PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT7175477

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
BIOGEN IDEC INTERNATIONAL HOLDING LTD.	08/19/2013

RECEIVING PARTY DATA

Name:	BIOGEN IDEC MA INC.
Street Address:	14 CAMBRIDGE CENTER
City:	CAMBRIDGE
State/Country:	MASSACHUSETTS
Postal Code:	02142

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	16357179

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 4155488633

Email: ip-squire@squirepb.com
Correspondent Name: TODD A. LORENZ

Address Line 1: 275 BATTERY STREET, SUITE 2600
Address Line 4: SAN FRANCISCO, CALIFORNIA 94111

ATTORNEY DOCKET NUMBER:	P1067US006
NAME OF SUBMITTER:	TODD A. LORENZ, REG. NO. 39,754
SIGNATURE:	/Todd A. Lorenz, Reg. No. 39,754/
DATE SIGNED:	02/14/2022

Total Attachments: 70

source=P1067_assign_BIOGEN_IDEC_INTL_HOLDING_to Biogen_Idec_MA_Inc#page1.tif
source=P1067_assign_BIOGEN_IDEC_INTL_HOLDING_to Biogen_Idec_MA_Inc#page2.tif
source=P1067_assign_BIOGEN_IDEC_INTL_HOLDING_to Biogen_Idec_MA_Inc#page3.tif
source=P1067_assign_BIOGEN_IDEC_INTL_HOLDING_to Biogen_Idec_MA_Inc#page4.tif
source=P1067_assign_BIOGEN_IDEC_INTL_HOLDING_to Biogen_Idec_MA_Inc#page5.tif
source=P1067_assign_BIOGEN_IDEC_INTL_HOLDING_to Biogen_Idec_MA_Inc#page6.tif

PATENT 507128637 REEL: 059098 FRAME: 0554

source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page7.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page8.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page9.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page10.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page11.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page12.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page13.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page14.tif source=P1067_assign_BIOGEN_IDEC_INTL_HOLDING_to Biogen_Idec_MA_Inc#page15.tif source=P1067 assign BIOGEN IDEC_INTL_HOLDING_to Biogen_Idec_MA_Inc#page16.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page17.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page18.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page19.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page20.tif source=P1067 assign BIOGEN IDEC_INTL_HOLDING_to Biogen_Idec_MA_Inc#page21.tif source=P1067_assign_BIOGEN_IDEC_INTL_HOLDING_to Biogen_Idec_MA_Inc#page22.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page23.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page24.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page25.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page26.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page27.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page28.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page29.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page30.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page31.tif source=P1067_assign_BIOGEN_IDEC_INTL_HOLDING_to Biogen_Idec_MA_Inc#page32.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page33.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page34.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page35.tif source=P1067_assign_BIOGEN_IDEC_INTL_HOLDING_to Biogen_Idec_MA_Inc#page36.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page37.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page38.tif source=P1067_assign_BIOGEN_IDEC_INTL_HOLDING_to Biogen_Idec_MA_Inc#page39.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA_Inc#page40.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page41.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page42.tif source=P1067 assign_BIOGEN_IDEC_INTL_HOLDING_to Biogen_Idec_MA_Inc#page43.tif source=P1067_assign_BIOGEN_IDEC_INTL_HOLDING_to Biogen_Idec_MA_Inc#page44.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page45.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page46.tif source=P1067_assign_BIOGEN_IDEC_INTL_HOLDING_to Biogen_Idec_MA_Inc#page47.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page48.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page49.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page50.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page51.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page52.tif source=P1067_assign_BIOGEN_IDEC_INTL_HOLDING_to Biogen_Idec_MA_Inc#page53.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page54.tif

source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page55.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA_Inc#page56.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page57.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page58.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page59.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page60.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page61.tif source=P1067_assign_BIOGEN_IDEC_INTL_HOLDING_to Biogen_Idec_MA_Inc#page62.tif source=P1067_assign_BIOGEN_IDEC_INTL_HOLDING_to Biogen_Idec_MA_Inc#page63.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page64.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page65.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page66.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page67.tif source=P1067 assign BIOGEN IDEC INTL HOLDING to Biogen Idec MA Inc#page68.tif source=P1067_assign_BIOGEN_IDEC_INTL_HOLDING_to Biogen_Idec_MA_Inc#page69.tif source=P1067_assign_BIOGEN_IDEC_INTL_HOLDING_to Biogen_Idec_MA_Inc#page70.tif

CONFIRMATION OF ASSIGNMENT AND ASSUMPTION (PATENT ASSETS)

This CONFIRMATION OF ASSIGNMENT AND ASSUMPTION AGREEMENT, (this "Confirmation"), is made and entered into by and between Biogen Idea International Holding Ltd., a corporation of Bermuda having a place of business at Canon's Court, 22 Victoria Street, Hamilton HM EX, Bermuda, ("Bermuda") and Biogen Idea MA Inc., a corporation of Massachusetts having a place of business at 14 Cambridge Center, Cambridge, Massachusetts 02142, ("BIMA"). Bermuda and BIMA are sometimes referred to herein individually as a "Party" and collectively as the "Parties."

WHEREAS, Bermuda is party to that certain Asset Purchase Agreement, among Bermuda, Elan Pharma International Limited and Elan Pharmaceuticals, Inc. dated as of February 5, 2013 (the "Asset Purchase Agreement");

WHEREAS, Bermuda and BIMA are parties to that certain Assignment and Assumption Agreement, dated as of April 2, 2013 (the "Assignment and Assumption Agreement");

WHEREAS, pursuant to the Asset Purchase Agreement Bermuda acquired the Transferred Assets (other than the Transferred Inventory) and assumed the Assumed Liabilities;

WHEREAS, the rights and resources acquired through the Asset Purchase Agreement have been added to the Intangible Development Activity as defined under the Tysabri R&D Cost Sharing Agreement between the Parties (as such agreement may be amended and restated from time to time) (the "CSA Agreement"), and the fair market value consideration set forth in the Assignment and Assumption Agreement was intended to satisfy BIMA's obligation to make PCT Payments as specified and as defined in such CSA Agreement;

WHEREAS, as set forth in the Assignment and Assumption Agreement, the Parties wish for purposes of administrative convenience and the defense of intangible property rights that BIMA acquire and hold legal title to, inter alia, all Patent Assets as defined below, subject to Bermuda's retention of beneficial ownership of all rights to the Ex-U.S. Patent Assets, as defined below, through a perpetual and exclusive royalty free license of such rights;

WHEREAS, pursuant to the terms of the Assignment and Assumption Agreement, the Parties intend (i) as described above, for legal title of the Patent Assets to be transferred and held by BIMA or a U.S. affiliate, (ii) for Bermuda to transfer to BIMA, and BIMA to receive and hold beneficial ownership of all U.S. Patent Assets, as defined below, and (iii) for Bermuda to retain beneficial ownership of all rights in the Ex-U.S. Patent Assets;

WHEREAS, pursuant to the terms of the Assignment and Assumption Agreement, the Parties wish to assign, transfer and convey to BIMA, and BIMA desires to assume and accept, all Assumed Liabilities to the extent related to the U.S. Patent Assets, (collectively, the "Assumed U.S. Patent Liabilities");

Confirmation of Assignment and Assumption Page 1 of 4

NOW, THEREFORE, in consideration of the covenants and agreements contained herein and in the Assignment and Assumption Agreement, and other good and valuable consideration, including as set forth in the Assignment and Assumption Agreement, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, the Parties agree as follows:

1. Definitions.

- a. Capitalized terms used herein but not defined herein have the respective meanings ascribed to them in the Asset Purchase Agreement and the Assignment and Assumption Agreement, and the rules of usage set forth therein shall apply hereto.
- b. "Patent Assets" shall mean U.S. Patent Assets and Ex-U.S. Patent Assets;
- c. "U.S. Patent Assets" shall mean:
 - i. Each of the patents and patent applications set forth in Schedule A, annexed hereto and made a part hereof:
 - ii. Any and all United States patents and patent applications that claim the benefit of the patents and patent applications set forth in Schedule A, including any and all United States utility patents and patent applications, including non-provisional, continuing (continuation, continuation-in-part or divisional), reissue, and reexamination applications, utility models, and design registrations;
 - iii. Any and all inventions described in each of the patents and patent applications set forth in Schedule A, and in all forms of intellectual and industrial property protection derivable therefrom, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patents and patent applications, including without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor, and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the United States, as may be applicable;
- d. "Ex-U.S. Patent Assets" shall mean:
 - i. Each of the patents and patent applications set forth in Schedule B, annexed hereto and made a part hereof;
 - ii. Any and all non-United States patents and patent applications that claim the benefit of the patents and patent applications set forth in Schedule B, including any and all non-United States utility patents and patent applications, including non-provisional, continuing (continuation, continuation-in-part or divisional), reissue, and reexamination applications, utility models, and design registrations;
 - iii. Any and all inventions described in each of the patents and patent applications set forth in Schedule B, and in all forms of intellectual and industrial property protection derivable therefrom, and that are derivable from any and all continuing applications, reissues,

Confirmation of Assignment and Assumption Page 2 of 4

extensions, renewals and reexaminations of such patents and patent applications, including without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor, and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable.

- 2. <u>Assignment of Title</u>. Bermuda hereby confirms that it has assigned, transferred and conveyed to BIMA all of its legal title to the Patent Assets, subject to Bermuda's retention of the perpetual and exclusive royalty-free license to the Ex-U.S. Patent Assets as specified in Section 5 of this Confirmation.
- 3. <u>Assignment of Rights and Beneficial Ownership of the U.S. Patent Assets</u>. Bermuda hereby confirms that it has assigned, transferred and conveyed to BIMA all of its right, title and interest in, and to the U.S. Patent Assets, including the right to sue for past infringement and to collect for all past, present and future damages.
- 4. Acceptance and Assumption of Rights and Liabilities. BIMA hereby (A) confirms its Acceptance of the assignment, transfer and conveyance of (i) title to the Patent Assets subject to Bermuda's retention of the perpetual and exclusive royalty free license of all rights to the Ex-U.S. Patent Assets specified in Section 5 of this Confirmation, (ii) the U.S. Patent Assets and (B) confirms its assumption of the Assumed U.S. Patent Liabilities, and its agreement to timely pay, honor, discharge and perform or otherwise satisfy when due, or cause to be timely paid, honored, discharged, performed or otherwise satisfied when due, all of the Assumed U.S. Patent Liabilities.
- 5. Grant of License. The assignment of legal title to the Patent Assets described in Section 2 of this Confirmation is subject to BIMA's grant and Bermuda's retention of an exclusive, perpetual, irrevocable royalty-free, fully paid up license, with the right to grant and authorize sublicenses, to the Ex-U.S. Patent Assets including, without limitation (i) to manufacture (or have manufactured) Products (as defined in the CSA Agreement) in all countries outside the United States ("the Ex-U.S. territory"), (ii) to use, license, sell, offer for sale, or import the Products in or into the Ex-U.S. Territory, (iii) to use, reproduce, distribute, perform or display the Products in the Ex-U.S. Territory, (iv) to make (or have made) modifications, enhancements or further developments to the Products under the IDA (as defined in the CSA Agreement) in the Ex-U.S. Territory and (v) to otherwise use and exploit the Ex-U.S. Patent Assets.
- 6. <u>Further Assurances</u>. Each Party hereby covenants and agrees that, without further consideration, it shall execute such documents and take such further action as any other Party may reasonably request in order to effectuate the assignments, transfers, conveyances and assumptions set forth herein.

Confirmation of Assignment and Assumption Page 3 of 4

- 7. Effectiveness. This Confirmation shall be effective as of April 2, 2013, immediately after the Closing. To the extent local law prohibits the assignment from Bermuda to BIMA of any specific patents or patent applications among the Patent Assets from being effective as of April 2, 2013, the assignment of said specific patents or patent applications shall be effective as of the first date on which such assignment is permitted under local law.
- 8. Governing Law. This Confirmation shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts without giving effect to principles of conflict of laws.
- 9. Successors and Assigns; Limitation on Rights of Others. The terms of this Confirmation shall be binding upon, and inure to the benefit of, the Parties and their respective legal representatives, successors and assigns. Nothing in this Confirmation, whether express or implied, shall be construed to give any Person (other than the Parties hereto and their respective successors and assigns) any legal or equitable right, remedy or claim under, or in respect of, this Confirmation or any covenants, conditions or provisions contained herein, as a third party beneficiary or otherwise.
- 10. Counterparts. This Confirmation may be executed in any number of counterparts, each of which shall be deemed as original, but all of which together shall constitute one instrument.

[Signature Pages Follow]

Confirmation of Assignment and Assumption Page 4 of 4

	SIGNED, (
	BlOGI	EN IDEC INTERNAT	IONAL HOLD	ING LTD.
	Ву:	Thuis .	<u>so(4)</u>	
	Name:	M. TOMESAN	<u> Ahissah</u>	
	Title:	DIRECTOR		
	Date:	19th August	<u> </u>	
Before me tl	nis	AUGUST	_, 20 <u>_1</u> %	_, personally
Assignment, proved	to me through satisfactor	2400044 0400000000000000000000000000000	fication in the i	form of
Assignment, proved	to me through satisfacto	ory evidence of identif acknowledged that he	fication in the i	form of
Assignment, proved	to me through satisfacto and deed for the purposes the	ory evidence of identifications acknowledged that he crein contained.	fication in the i	form of
Assignment, proved	to me through satisfactor, and leed for the purposes the	ory evidence of identif acknowledged that he	fication in the factorial	form of
Assignment, proved	to me through satisfactory, and leed for the purposes the N	ory evidence of identifications acknowledged that he erein contained. Output District Public	fication in the factorial	form of
Assignment, proved PASSIBLE his/her free act and of	to me through satisfactory, and leed for the purposes the N	ory evidence of identifications acknowledged that he erein contained. Output District Public	fication in the factorial	form of

Signature Page to Confirmation of Assignment and Assumption

BIOGEN IDEC MA.INC.

Ву	Rynne Juli
Na	me: Lynne Sullwan
Titl	e: VP Tax
Dat	e: <u>8-19-13</u>
appeared <u>selling and</u> known to me to be Assignment, proved to me through satisfi	10 Migus
	Notary Public
and the second of the second o	My Commission Expires:
[Notary's Seal Here]	

Signature Page to Confirmation of Assignment and Assumption

PATENT REEL: 059098 FRAME: 0562

AUDREY WILLIAMS

Notary Pubro

COMMONWEAUTH OF MASSACHUSETTS

My Commission Expires

July 29, 2016

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0002-PR	61/406,358	Oct-25-2010		METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN SVCAM AND/OR SMAdCAM LEVELS
ELN-0002-PR1	61/406,365	Oct-25-2010		METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN
ELN-0002-US	13/881,520	Oct-24-2011		SVCAM AND/OR SMAdCAM LEVELS METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IS SVCAM AND/OR SMAdCAM LEVELS

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0003-US	11/711,628	Feb-28-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0003-US-D1	12/757,305	Apr-09-2010		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0004-US	11/713,000	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZIIMAB
ELN-0004-US-C1	13/425,058	Mar-20-2012		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0007-US	07/413,274	Sep-27-1989		BLOOD-BRAIN BARRIER MODEL
ELN-0007-US-C1	08/402,962	Mar-10-1995		COMPOSITIONS AND METHODS FOR MODULATING LEUKOCYTE ADHESION TO BRAIN ENDOTHELIAL CELLS
ELN-0007-US-C2	08/457,847	Jun-01-1995	6,033,665	COMPOSITIONS AND METHODS FOR MODULATING LEUKOCYTE ADHESION TO BRAIN ENDOTHELIAL CELLS
ELN-0007-US- CIP1	07/577,650	Sep-04-1990	5,260,210	BLOOD-BRAIN BARRIER MODEL
ELN-0007-US- CIP2	07/871,223	Apr-17-1992		COMPOSITIONS AND METHODS FOR MODULATING LEUKOCYTE ADHESION TO BRAIN ENDOTHELIAL CELLS

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0008-US	08/186,269	Jan-25-1994		HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION
ELN-0008-US- CIP1	08/561,521	Nov-21-1995	5,840,299	MOLECULE VLA-4 HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-US02	09/155,739	Nov-21-1996		THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN
ELN-0008-US-C1	11/006,808	Dec-08-2004	7,435,802	HUMANIZED ANTI-VLA4
ELN-0008-US-C2	12/175,116	Jul-17-2008	8,246,958	IMMUNOGLOBINS METHODS OF INHIBITING ALPHA-4 DEPENDENT INTERACTIONS WITH VCAM-1 WITH ANTI-VLA-4 ANTIONNESS
ELN-0008-US-C3	13/540,462	Jul-02-2012		ANTIBODIES THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN

A&P File Reference	Explineation 140.	Application Date	Registration No.	Title
ELN-0009-PR1	60/360,134	Feb-25-2002		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF
ELN-0009-PR2	60/374,501	Apr-23-2002		INFLAMMATION ADMINISTRATION OF AGENTS FOR THE TREATMENT OF
ELN-0009-US	10/372,111	Feb-25-2003		INFLAMMATION ADMINISTRATION OF AGENTS FOR THE TREATMENT OF
ELN-0009-US-D1	11/540,640	Oct-02-2006	7,807,167	INFLAMMATION ADMINISTRATION OF AGENTS FOR THE TREATMENT OF
ELN-0009-US-D2	12/846,350	Jul-29-2010		INFLAMMATION ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0010-PR1	60/442,171	Jan-24-2003		REVERSAL OF INFLAMMATORY RESPONSE BY INHIBITION OF ALPHA-4 INTEGRIN TO INHIBIT DEMYELINATION
ELN-0010-PR2	60/500,316	Sep-05-2003	<u>.</u>	REVERSAL OF INFLAMMATORY RESPONSE BY INHIBITION OF ALPHA-4 INTEGRIN TO INHIBIT DEMYELINATION AND REVERSE PARALYSIS
ELN-0010-US1	10/763,424	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-US2	10/763,539	Jan-26-2004	7,576,101	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS

SCHEDULE A TO PATENT ASSIGNMENT PAGE 2 OF 11

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0011-PR	60/445,818	Feb-10-2003		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-PR1	60/929,133	Jun-14-2007		LYOPHILIZED IMMUNOGLOBULIN FORMULATION AND METHDS OF PREPARATION
ELN-0011-US	10/773,406	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF
ELN-0011-US-C2	12/572,978	Oct-02-2009	8,349,321	PREPARATION THEREOF IMMUNOGLOBULIN FORMULATION AND METHD OF
ELN-0011-US2	13/605,590	Sep-06-2012		PREPARATION THEREOF IMMUNOGLOBULIN FORMULATION AND METHD OF
ELN-0011-US3	13/676,866	Nov-14-2012	***************************************	PREPARATION THEREOF IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF

A&P File	***************************************	ş	***************************************	· · · · · · · · · · · · · · · · · · ·
Reference	3 whbucanou 140.	Application Date	Registration No.	Trial
ELN-0012-PR	60/541,946	Feb-06-2004		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND
ELN-0012-US	11/049,365	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND
	***************************************			METASTATIC DISEASE

A&P File Reference	Application No.	Application Date	Registration No.	Title
Commission of the Commission o	£			Title
ELN-0013-PR	60/558,120	Apr-01-2004		STEROID SPARING AGENTS AND
\$ monoment management of the second	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		***************************************	METHODS OF HEINIG THE CAME
ELN-0013-PR1	60/558,121	Apr-01-2004		STEROID SPARING AGENTS AND
A			***************************************	METHODS OF USING SAME
ELN-0013-US1	11/095,822	Apr-01-2005		STEROID SPARING AGENTS AND
				METHODS OF USING THE SAME
ELN-0013-US2	11/096,074	Apr-01-2005		STEROID SPARING AGENTS AND
£				METHODS OF USING THE SAME

F&L Docket No.	Title	Country	Application Number	Appl Date	Patent Number	Grant Date
342837-1451	CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	09/987619	11/15/200	6900179	5/31/2005
342837-1453	CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	10/316205	12/11/200	7320960	1/22/2008
342837-1454	Anti-Inflammatory Compositions and Method	United States of America	09/127364	7/31/1998	6939855	9/6/2005

SCHEDULE A TO PATENT ASSIGNMENT PAGE 3 OF 11

F&L Docket	Title	Country	Application	Appl Date	Patent	Grant Date
No.			Number		Number	
342837-1450	COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	09/126958	7/31/1998	6489300	12/3/2002
342837-1487	CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	11/128732	5/13/2005	7229970	6/12/2007
342837-1452	CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	09/987900	11/16/200	6525026	2/25/2003
342837-1488	Anti-Inflammatory Compositions and Methods	United States of America	11/147601	6/7/2005		
342837- 1450X	CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	60/112020	7/31/1997		
342837- 1451/X/X	CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	08/904424	7/31/1997		
342837- 1451X	CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	60/054453	8/1/1997		
342837-1550	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	United States of America	09/489377	1/21/2000	6492372	12/10/2002
342837-1551	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	United States of America	10/218366	8/15/2002	6911439	6/28/2005
342837-1553	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	United States of America	10/748089	12/29/200 3	7005433	2/28/2006

SCHEDULE A TO PATENT ASSIGNMENT PAGE 4 OF 11

F&L Docket No.	Title	Country	Application Number	Appl Date	Patent	Grant Date
342837-1582	Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	United States of America		1/10/2005	7378529	5/27/2008
342837-1585	Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	United States of America	12/645154	12/22/200	ł.	7/5/2011
342837-2400	Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	United States of America	09/489378	1/21/2000	6479492	11/12/2002
342837-2401	Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	United States of America	10/218445	8/15/2002	6903088	6/7/2005
342837-2416	Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	United States of America	11/145489	6/2/2005	7538215	5/26/2009
342837-1584	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	United States of America	11/582293	10/16/200	7741328	6/22/2010
342837-1552	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated BYVLA-4	United States of America	10/251442	9/20/2002	7049306	5/23/2006
342837-1586	HETEROARYL, HETEROCYCLIC AND ARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	12/637719	12/14/200	7968547	6/28/2011
	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	United States of America	60/116923	1/22/1999		

Schedule A To Patent Assignment Page 5 OF 11

F&L Docket No.	Title	Country	Application Number	Appl Date	Patent Number	Grant Date
342837-	Heteroaryl,	United States of		10/21/199		
1551X	Heterocyclic and Aryl	America	00, 200333	10/21/199	1	
	Compounds Which			9		
	Inhibit Leukocyte					
	Adhesion Mediated					
	by VLA-4		1			
342837-3899	11-7-11-11	United States of	60/117760	1/29/1999		
	HETEROCYCLIC AND	America			1	
	ARYL COMPOUNDS					
	WHICH INHIBIT					
	LEUKOCYTE		1	•		
	ADHESION	j			1	
	MEDIATED BY VLA-4 -					
342837-2080	US					
342637-2080	Heteroaryl, Heterocyclic and Aryl	United States of	60/168188	11/30/199		
'	Compounds Which	America		9		
	Inhibit Leukocyte					
	Adhesion Mediated					
	by VLA-4				1	
342837-1651	FUSED RING	United States of	10/31/190	40/44/500	ļ	
	HETEROARYL AND	America	10/316189	12/11/200	7452912	11/18/2008
	HETEROCYCLIC	America		2		
	COMPOUNDS WHICH				[
	INHIBIT LEUKOCYTE				1	
	ADHESION		į			
	MEDIATED BY VLA-4					
342837-1650	FUSED RING	United States of	09/489271	1/21/2000	6545003	4/8/2003
	HETEROARYL AND	America	•	1,22,2000	0345005	4/0/2003
	HETEROCYCLIC					
	COMPOUNDS WHICH					
	INHIBIT LEUKOCYTE					
	ADHESION					
	MEDIATED BY VLA-4					
342837-	FUSED RING	United States of	60/116967	1/22/1999		
1650X	HETEROARYL AND	America				
	HETEROCYCLIC					
	COMPOUNDS WHICH					
	INHIBIT LEUKOCYTE					
	ADHESION					
342837-	MEDIATED BY VLA-4					
1651X	FUSED RING	United States of	60/117742	1/29/1999		
70JIN	HETEROARYL AND HETEROCYCLIC	America				
	COMPOUNDS WHICH					
	INHIBIT LEUKOCYTE					
	ADHESION					1
	MEDIATED BY VLA-4					1
342837-2151	Alpha Aminocetic	United States of	10/147004	5/20/2005	5545455	
	Acid Derivatives-	United States of America	10/147884	5/20/2002	6545160	4/8/2003
1	Alpha 4 Beta 7	AITICILIA				
	Receptor Antagonists	Ī				
<u>1</u>				J		

SCHEDULE A TO PATENT ASSIGNMENT PAGE 6 OF 11

F&L Docket No.	Title	Country	Application Number	Appl Date	Patent Number	Grant Date
342837-2150	Acid Derivatives - Alpha4Beta7 Receptor Antagonists	United States of America		2/28/2000		6/25/2002
342837- 2150X	Alpha Aminoacetic Acid Derivatives- Alpha 4 Beta 7 Receptor Antagonists	United States of America	60/122071	3/1/1999		
342837-1852	ALPHA AMINO ACID DERIVATIVES- INHIBITORS OF LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	10/936070	9/7/2004	7745454	6/29/2010
342837-1850 342837-	Alpha Amino Acid Derivatives Inhibitors of Leukocyte Adhesion Mediated by VLA-4	United States of America	09/910702	7/20/2001		
1850X	Alpha Amino Acid Derivatives Inhibitors of Leukocyte Adhesion Mediated by VLA-4	United States of America	60/220132	7/21/2000		
342837-1950	3-(Heteroaryl)alanine Derivatives Inhibitors of Leukocyte Adhesion Mediated by VLA-4	United States of America	09/910466	7/19/2001	6794506	9/21/2004
342837-1952	3-(Heteroaryl) Alanine Derivatives- Inhibitors of Leukocyte Adhesion Mediated by VLA-4	United States of America	10/898576	7/23/2004	7365073	4/29/2008
342837-1953	3-(Heteroaryl)alanine Derivatives Inhibitors of Leukocyte Adhesion Mediated by VLA-4	United States of America	11/873358	10/16/200 7		
342837- 1950X	3-(HeteroaryI)alanine Derivatives Inhibitors of Leukocyte Adhesion Mediated by VLA-4	United States of America	60/220131	7/21/2000		
	Heterocyclic Compounds Which Inhibit Leukocyte Adhesion Mediated By Alpha-4 Integrins	United States of America	11/527901	5/27/2003	7427628	9/23/2008

Schedule A To Patent Assignment Page 7 OF 11 $\,$

F&L Docket	Title	Country	Application	Appl Date	Patent	Grant Date
342837-1355	LIETERORYOUR		Number		Number	
342037-1333	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	United States of America	10/494790	5/27/2003	7135477	11/14/2006
342837-1350	COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	United States of America	10/447308	5/27/2003	7026328	4/11/2006
342837-4011	PYRIMIDINE HYDANTOIN ANALOGUES WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	11/118862	4/29/2005	7205310	4/17/2007
342837-4010	PYRIMIDINE HYDANTOIN ANALOGUES WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	60/566784	4/30/2004		
342837-4050	Carbamate Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	United States of America	60/722355	9/29/2005		
342837-4053	CARBAMATE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	12/759419	4/13/2010	8367688	2/5/2013
342837-4051	Carbamate Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	United States of America	11/541205	9/28/2006	7727996	6/1/2010
342837-4052	CARBAMATE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	12/579828	10/15/200	8158642	4/17/2012
342837-4054	CARBAMATE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	United States of America	13/416997	3/9/2012		

SCHEDULE A TO PATENT ASSIGNMENT PAGE 8 OF 11

F&L Docket No.	Title	Country	Application Number	Appl Date	Patent	Grant Date
342837-5002	PYRIMIDINYL AMIDE	United States o			Number	
	COMPOUNDS WHICH	America	f 12/352543	1/12/2009	7763632	7/27/201
	INHIBIT LEUKOCYTE	America				
	ADHESION			1		
	MEDIATED BY VLA-4					
342837-5001		United States o				
	Compounds Which		11/529815	9/28/2006	7511052	3/31/200
	Inhibit Leukocyte	America				-,-2,200
	Adhesion Mediated		1			
	by VLA-4			- 1	1	
342837-5000	Pyrimidinyl amide	Haita I Gran				
	compounds which	United States of	60/722358	9/29/2005		
	inhibit leukocyte	America			1	
	adhesion mediated					
	by VLA-4				ł	
342837-5052	PYRIMIDINYL	 				
203/ 303 <u>2</u>	SULFONAMIDE	United States of	12/505383	7/17/2009	7820687	10/26/2010
	COMPOUNDS WHICH	America				10,20,201
	INHIBIT LEUKOCYTE				1	
	ADHESION					
	MEDIATED BY VLA-4				1	
342837-5051	Pyrimidinyl	11.2. 10.				
	Sulfonamide	United States of	11/679042	2/26/2007	7579466	8/25/2009
	Compounds Which	America				,,
	Inhibit Leukocyte					
	Adhesion Mediated					
	By VLA-4					
342837-5050	Pyrimidinyl	United States of				
	Sulfonamide	America	60/777595	2/27/2006		
	Compounds Which	America				
	Inhibit Leukocyte					
	Adhesion Mediated					
	By VLA-4					
42837-5151	PYRIDINONE	United States of	13/700000	 		
	ANTAGONISTS OF	America	12/768680	4/27/2010	8367836	2/5/2013
	ALPHA-4 INTEGRINS	America				
42837-5152		United States of	12/720522	10/0-10		
	ANTAGONISTS OF	America	13/730522	12/28/201		
	ALPHA-4 INTEGRINS	, interieu		2		
42837-5150		United States of	61/172076	1/2-/		
1	ANTAGONISTS OF	America	61/172876	4/27/2009		
	ALPHA-4 INTEGRINS	,ici rea			İ	
42837-1150		United States of	09/126095	7/20/4000	CARCITE	
		America	03/120033	7/30/1998	6492421	12/10/2002
l	Compounds Which					
	Inhibit Leukocyte					
1	Adhesion Mediated					
	by VLA-4			1	ļ	

SCHEDULE A TO PATENT ASSIGNMENT PAGE 9 OF 11

F&L Docket No.	Title	Country	Application	Appl Date	Patent	Grant Date
342837- 1150X	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	United States of America	Number 60/104599	7/31/1997	Number	
		United States of America	08/920394	7/31/1998		

MBHB Case No.	Application No. / Patent No.	Date	Title
05-052	USSN60/586,975	(mm/dd/yyyy))
	0001100/380,975	07/08/2005	Multimeric VIa-4 Antagonist Compressing
05-119	USSN60/683,509	05/20/2005	
05-051-PRO	USSN60/538573	05/20/2005 01/23/2004	Imidazolone Phenylalanine Derivatives
		01/23/2004	Heterocycloalkyl Carboxamido Propagoid
05-553	USSN60/697,726	07/08/2005	Acius
		07/08/2005	Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food
05-881	USSN60/802,349	05/00/0000	Additive Compounds
	1010	05/22/2006	Preparation Of Polymer Conjugates Of
0.5.00		1	Interapeutic, Agricultural, And Food
05-881-A	US8,138,272	03/20/2012	Additive Compounds
		00/20/2012	Preparation Of Polymer Conjugates Of
05-553-A			Therapeutic, Agricultural, And Food
00-000-M	US8,268,935	09/18/2012	Additive Compounds
			Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food
05-051-A	US7,595,318		Additive Compounds
	037,595,318	09/29/2009	Polyethylene Glycol Conjugates Of
	j		Heterocycloalkyl Carboxamido Propanoic
5-119-A	US8,030,328	40/01/0	Acids
	1	10/04/2011	Imidazolone Phenylalanine Derivatives As
5-052-A-CON	US8,263,063	09/11/2012	VLA-4 Antagonists
		09/11/2012	Multimeric VIa-4 Antagonist Compressing
5-052-A	US7,794,700	09/14/2010	Polymer Moleties
F 050		30/14/2010	Multimeric VIa-4 Antagonist Compressing
5-052-A-CON2	13/606783	09/07/2012	Polymer Moleties Multimorio Vila de la companya del la companya de la companya d
F 050 A 00110		1	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
5-052-A-CON3	13/831625	03/15/2013	Multimeric VIa 4 Antogonist Co
· · · · · · · · · · · · · · · · · · ·		1	Multimeric Vla-4 Antagonist Compressing Polymer Moieties

Country	Serial No.	Filing Date	B 111		
United States	60/668404	04-Apr-05	Publication No.	Patent No.	Grant Date
United States 01			TYGGG		
United States 02	13/242505	0.0.0	US2009-0176256	8124350	28-Feb-12
		23-Sep-11	US2012-0195884		

SCHEDULE A TO PATENT ASSIGNMENT PAGE 11 OF 11

A&P File Reference	Application No.	Application Date	Registration No.	The state of the s
ELN-0002-AU	2011323820	Oct-24-2011		Title METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY
ELN-0002-CA	2,816,016	Oct-24-2011		CORRELATING DIFFERENCES IS SVCAM AND/OR SMADCAM LEVELS METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY
ELN-0002-EP	11838481.7	Oct-24-2011		CORRELATING DIFFERENCES IS SVCAM AND/OR SMACCAM LEVELS METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY
ELN-0002-JP	TBD	Oct-24-2011		CORRELATING DIFFERENCES IS SVCAM AND/OR SMAdCAM LEVELS METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY
LN-0002-WO	PCT/US2011/057519	Oct-24-2011		CORRELATING DIFFERENCES IS SVCAM AND/OR SMAdCAM LEVELS METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IS

Reference	Application No.	Application Date	***************************************	
	., p	Application Date	Registration No.	Title
	}	100-20-200/		Title METHODS OF TREATING INFLAMMATORY AND
ELN-0003-EP	07751683.9	Feb-28-2007		AUTOIMMUNE DISEASES WITH NATALIZUMAB METHODS OF TREATING INFLAMMATORY AND
ELN-0003-EP-D1	13175987.0	Feb-28-2007		AUTOIMMUNE DISEASES WITH NATALIZUMAB METHODS OF TREATING INFLAMMATORY AND
LN-0003-JP	2008-557327	Feb-28-2007		AUTOIMMUNE DISEASES WITH NATALIZUMAB METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH
LN-0003-WO	PCT/US2007/004943	Feb-28-2007		METHODS OF TREATING INFLAMMATORY AND
			***************************************	AUTOIMMUNE DISEASES WITH NATALIZUMAB

A&P File Reference	Application No.	A	Registration No.	NATALIZUMAB
ELN-0004-AU	2007224228	Mar-02-2007	announcement to the second	Title
ELN-0004-BR	PI 0708392-0	Mar-02-2007		NATALIZUMAB METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH
ELN-0004-CA	2,644,110	Mar-02-2007		NATALIZUMAB METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH
LN-0004-CN	200780015815.5	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND
	hummummmmmh			AUTOIMMUNE DISEASES WITH NATALIZUMAB

A&P File Reference	Applicat	tion No.	Application Da	ate	Registration N	0 Tid-
ELN-0004-	08.105.67	6	Mar-02-2007			METHODS OF TREATING
ELN-0004-I	00000					INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
	080582		Mar-02-2007		6107	METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH
ELN-0004-E	A 200801933		Mar-02-2007		016626	METHODS OF TREATING INFLAMMATORY AND
ELN-0004-E	PCT-08-87	38	Mar-02-2007			AUTOIMMUNE DISEASES WITH NATALIZUMAB METHODS OF TREATING INFLAMMATORY AND
ELN-0004-E(1440/2008		Mar-02-2007		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	AUTOIMMUNE DISEASES WITH NATALIZUMAB METHODS OF TREATING
ELN-0004-EP	07751993.2					AUTOIMMUNE DISEASES WITH NATALIZUMAR
			Mar-02-2007			METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WELL
ELN-0004-ID	W002008031	72	Mar-02-2007			METHODS OF TREATING INFLAMMATORY AND
ELN-0004-IL	193775		Mar-02-2007		193775	AUTOIMMUNE DISEASES WITH NATALIZUMAB METHODS OF TREATING INFLAMMATORY AND
ELN-0004-IN	8058/DELNP/2	2008	Mar-02-2007			AUTOIMMUNE DISEASES WITH NATALIZUMAB METHODS OF TREATING
ELN-0004-JP	2008-558307			ļ		AUTOIMMUNE DISEASES WITH NATALIZUMAB
***************************************	2006-338307	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Mar-02-2007			METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-JP-DI	2012-264135		Mar-02-2007			METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH
LN-0004-KR	10-2008-702346	4	Mar-02-2007			METHODS OF TREATING INFLAMMATORY AND
-N-0004-MA	PV/31249		Mar-02-2007	***************************************	30287	AUTOIMMUNE DISEASES WITH NATALIZUMAB METHODS OF TREATING INFLAMMATORY AND
N-0004-MX	MX/a/2008/01117	76	Mar-02-2007			AUTOIMMUNE DISEASES WITH NATALIZUMAB METHODS OF TREATING
N-0004-MY	PI 20083409					AUTOIMMUNE DISEASES WITH NATALIZUMAB METHODS OF TREATING
V-0004-NZ			Mar-02-2007	***************************************		AUTOIMMUNE DISEASES WITH NATALIZUMAB
	570852		Aar-02-2007			METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH
I-0004-NZ-	596359	M	far-02-2007			METHODS OF TREATING INFLAMMATORY AND
						AUTOIMMUNE DISEASES WITH NATALIZUMAB

SCHEDULE B TO PATENT ASSIGNMENT PAGE 2 OF 53

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0004-NZ-D2	610405	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH
ELN-0004-PH	1-2008-501982	Mar-02-2007		NATALIZUMAB METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH
ELN-0004-RS	P-391/2008	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND
ELN-0004-SG	200806732-4	Mar-02-2007	146063	AUTOIMMUNE DISEASES WITH NATALIZUMAB METHODS OF TREATING INFLAMMATORY AND
ELN-0004-SG-D1	201101499-0	Mar-02-2007	***************************************	AUTOIMMUNE DISEASES WITH NATALIZUMAB METHODS OF TREATING INFLAMMATORY AND
LN-0004-WO	PCT/US2007/005265	Mar-02-2007		AUTOIMMUNE DISEASES WITH NATALIZUMAB METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH
LN-0004-ZA	2008/07346	Mar-02-2007	2008/07346	NATALIZUMAB METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH

Application No.	Application Data		
, , , , , , , , , , , , , , , , , , ,	pprention Date	Registration No.	Title
2,066,738	Sep-13-1990	2,066,738	BI OOD DRADIDAD
2-513040	daniminiminiminiminimini		DECOD-BRAIN BARRIER MODEL
2-313049	Sep-13-1990	3308526	BLOOD-BRAIN BARRIER MODEL
2001-398632	E 12.45		- MACE A WOODEL
	Sep-13-1990		BLOOD-BRAIN BARRIER MODEL
	2,066,738 2-513049 2001-398632	2,066,738 Sep-13-1990 2-513049 Sep-13-1990 2001-398632 Sep-13-1990	2,066,738 Sep-13-1990 2,066,738 2-513049 Sep-13-1990 3308526

Reference	Application No.	Application Date	Registration No.	Title
ELN-0008-AT	95908741.2	Jan-25-1995	000 4	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION
ELN-0008-AU	16960/95	Jan-25-1995	703152	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADJESTON
ELN-0008-BE	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION
ELN-0008-CA1	2,182,013	Jan-25-1995	2,182,013	MOLECULE VLA-4 HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION
ELN-0008-CA2	2,237,808	Nov-21-1996		MOLECULE VLA-4 THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN
LN-0008-CH	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4

SCHEDULE B TO PATENT ASSIGNMENT PAGE 3 OF 53

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0008-CN	95191354.9	Jan-25-1995	ZL95191354.9	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION
ELN-0008-DE	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES
ELN-0008-DK	95908741.2	Jan-25-1995	000.403-	AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4 HUMANIZED ANTIBODIES
ELN-0008-EP1	95908741.2	Jan-25-1995	0804237	AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4 HUMANIZED ANTIBODIES
ELN-0008-EP2	96943512.2		0804237	AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
		Nov-21-1996		THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN
ELN-0008-EP-D	06013916.9	Jan-25-1995	1759709	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION
ELN-0008-ES	95908741.2	Jan-25-1995	0804237	MOLECULE VI.A-4 HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION
ELN-0008-FI	962958	Jan-25-1995	117509	MOLECULE VLA-4 HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION
ELN-0008-FR	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES
ELN-0008-GB	95908741.2	Jan-25-1995	0804237	AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4 HUMANIZED ANTIBODIES
ELN-0008-GR	95908741.2	Jan-25-1995		AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4 HUMANIZED ANTIBODIES
ELN-0008-HU	P9602019		0804237	AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4 HUMANIZED ANTIBODIES
ELN-0008-IE		Jan-25-1995	220,799	AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-IT	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-JP1	7-519770	Jan-25-1995	4115517	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION
LN-0008-JP2	9-519938	Nov-21-1996		MOLECULE VLA-4 THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN
LN-0008-JP-D1	2005-228930	Jan-25-1995		HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION
LN-0008-JP-DIV	2008-153420	Nov-21-1996		MOLECULE VLA-4 THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN
_N-0008-JP-D2	2009-120421	Jan-25-1995		HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION
.N-0008-JP-D3	2013-28635	Jan-25-1995		MULECULE VLA-4 HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION
N-0008-JP-D4	2013-54628	Jan-25-1995		MOLECULE V.LA-4 HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION
N-0008-KR	10-1996-0703987	Jan-25-1995	367948	MOLECULE VLA-4 HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION

SCHEDULE B TO PATENT ASSIGNMENT PAGE 4 OF 53

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0008-LU	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION
ELN-0008-MC	95908741.2	Jan-25-1995	0804237	MOLECULE VLA-4 HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION
ELN-0008-MX	962971	Jan-25-1995	198845	MOLECULE VLA-4 HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION
ELN-0008-NL	95908741.2	Jan-25-1995	0804237	MOLECULE VLA-4 HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION
ELN-0008-NO	19963097	Jan-25-1995	319.867	MOLECULE VLA-4 HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION
ELN-0008-NZ	279730	Jan-25-1995	279730	MOLECULE VIA-4 HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION
ELN-0008-PL	P315634	Jan-25-1995	181827	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION
ELN-0008-PT	95908741.2	Jan-25-1995	0804237	MOLECULE VI.A-4 HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION
LN-0008-SE	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION
LN-0008-WO01	PCT/US1995/001219	Jan-25-1995		HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION
LN-0008-WO02	PCT/US1996/018807	Nov-21-1996		MOLECULE VLA-4 THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN

Reference	Application No.	Application Date	Registration No.	Title
ELN-0009-AR	P030100608	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF
ELN-0009-AT	03709277.2	Feb-25-2003	1485127	INFLAMMATION ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009 AU	2003213231	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF
ELN-0009-AU-D1	2009201587	Feb-25-2003	2009201587	INFLAMMATION ADMINISTRATION OF AGENTS FOR THE TREATMENT OF
ELN-0009-AU-D2 .	2012202155	Feb-25-2003	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	INFLAMMATION ADMINISTRATION OF AGENTS FOR THE TREATMENT OF
ELN-0009-BE	03709277.2	Feb-25-2003	1485127	INFLAMMATION ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
LN-0009-BG	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
LN-0009-BR	PI0307975-9	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION

SCHEDULE B TO PATENT ASSIGNMENT PAGE 5 OF 53

A&P File Reference	Application	No. Application 1	Date Registration	No.
ELN-0009-C	A 2,477,178		The state of the s	
		Feb-25-200	***************************************	ADMINISTRATION OF AGENTS FO THE TREATMENT OF INFLAMMATION
ELN-0009-CF	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-CL	357-2003	Feb-25-2003		ADMINISTRATION OF A CENTRAL
ELN-0009-CN	03809138.0	Feb-25-2003	ZL03809138.	INFLAMMATION ADMINISTRATION OF AGENTS FOR THE TREATMENT OF
ELN-0009-CO	04095478	Feb-25-2003		INFLAMMATION ADMINISTRATION OF
ELN-0009-CY	03709277.2	Feb-25-2003		INFLAMMATION ADMINISTRATION OF A CONTROL
ELN-0009-CZ			1485127	THE TREATMENT OF INFLAMMATION
	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-DE	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-DK	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF
ELN-0009-EE	03709277.2	Feb-25-2003	1485127	INFLAMMATION ADMINISTRATION OF AGENTS FOR THE TREATMENT OF
ELN-0009-EG	191/2003	Feb-25-2003		ADMINISTRATION OF A COLUMN
ELN-0009 - EP	03709277.2	Feb-25-2003	,	INFLAMMATION ADMINISTRATION OF A CENTRE OF
LN-0009-EP-D1	10012870.1	Feb-25-2003	1485127	INFLAMMATION
LN-0009-EP-D2	10012871.9	Feb-25-2003		ADMISSION OF AGENTS FOR THE TREATMENT OF INFLAMMATION ADMINISTRATION OF AGENTS FOR
LN-0009-EP-D3	10012872.7	Feb-25-2003		INFLAMMATION ADMINISTRATION OF A CENTRE FOR
-N-0009-ES	03709277.2	Feb-25-2003	1485127	INFLAMMATION ADMINISTRATION OF AGENTS FOR THE TREATMENT OF
N-0009-FI	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF
V-0009-FR	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF
1-0009-GB	03709277.2	Feb-25-2003	1485127	INFLAMMATION ADMINISTRATION OF AGENTS FOR THE TREATMENT OF

SCHEDULE B TO PATENT ASSIGNMENT PAGE 6 OF 53

Reference	Application No.	Application Date	Registration No.	Title
ELN-0009-GR	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FO THE TREATMENT OF INFLAMMATION
ELN-0009-HK	05105001.1	Feb-25-2003	1073997	ADMINISTRATION OF AGENTS FO THE TREATMENT OF INFLAMMATION
ELN-0009-HK-D1	11113804.6	Feb-25-2003		ADMISSION OF AGENTS FOR THE
ELN-0009-HK-D2	12101864.7	Feb-25-2003		ADMINISTRATION OF AGENTS FO THE TREATMENT OF
ELN-0009-HK-D3	11107644.2	Feb-25-2003		INFLAMMATION ADMISSION OF AGENTS FOR THE
ELN-0009-HU	03709277.2	Feb-25-2003	1485127	TREATMENT OF INFLAMMATION ADMINISTRATION OF AGENTS FO THE TREATMENT OF INFLAMMATION
ELN-0009-ID	W-00200402079	Feb-25-2003		ADMINISTRATION OF AGENTS FOI THE TREATMENT OF INFLAMMATION
ELN-0009-IE	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-IL	163725	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-IL-D1	203515	Feb-25-2003	***************************************	COMPOSITION COMPRISING A - 4 - INTEGRIN FOR TREATING INFLAMMATION
ELN-0009-IN	2103/CHENP/2004	Feb-25-2003	229010	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-IN-D1	2196/CHENP/2008	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-IT	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
LN-0009-JP	2003-570787	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
LN-0009-JP-D1	2011-015696	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
LN-0009-KR	10-2004-7013609	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF
_N-0009-LU	03709277.2	Feb-25-2003	1485127	INFLAMMATION ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
.N-0009-MC	03709277,2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
N-0009-MX	PA/a/2004/008267	Feb-25-2003	310728	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION

SCHEDULE B TO PATENT ASSIGNMENT PAGE 7 OF 53

Reference	Application No.	Application Date	Registration No.	Title
ELN-0009-MY	PI20030650	Fcb-25-2003		ADMINISTRATION OF AGENTS FO THE TREATMENT OF INFLAMMATION
ELN-0009-NL	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FO THE TREATMENT OF INFLAMMATION
ELN-0009-NO	20044054	Feb-25-2003		ADMINISTRATION OF AGENTS FO THE TREATMENT OF INFLAMMATION
ELN-0009-NZ	535320	Feb-25-2003	535320	ADMINISTRATION OF AGENTS FO THE TREATMENT OF INFLAMMATION
ELN-0009-NZ-D1	566530	Feb-25-2003	arianiminaniminaniminaniminaniminaniminaniminaniminaniminaniminaniminaniminaniminaniminaniminaniminaniminanimi	ADMINISTRATION OF AGENTS FO THE TREATMENT OF
ELN-0009 -NZ-D2	579583	Feb-25-2003	579583	INFLAMMATION ADMINISTRATION OF AGENTS FO THE TREATMENT OF
ELN-0009-NZ-D3	591635	Feb-25-2003	591635	INFLAMMATION ADMINISTRATION OF AGENTS FO THE TREATMENT OF INFLAMMATION
ELN-0009-PE	195-03	Feb-27-2003		INFLAMMATION ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-PH	1-2004-501449	Feb-25-2003	1-2004-501449	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-PH-D1	1-2011-502301	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-PK	0161/03	Feb-26-2003	138459	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
LN-0009-PL	P-372306	Feb-25-2003	P-372306	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
LN-0009-PT	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
LN-0009-RU	2004128454	Feb-25-2003	235967	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
-N-0009-SA	03 24 0276	Sep-02-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
.N-0009-SE	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
N-0009-SG	200404939-1	Feb-25-2003	107209 [WO 03/072040]	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
N-0009-SI	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
N-0009-SK	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION

SCHEDULE B TO PATENT ASSIGNMENT PAGE 8 OF 53

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0009-TH	080345	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF
ELN-0009-TR	03709277.2	Feb-25-2003	1485127	INFLAMMATION ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-TW	092103902	Feb-25-2003	1346558	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF
ELN-0009-TW-D1	100112502	May-03-2011		INFLAMMATION PHARMACEUTICAL COMPOSITION FOR DETERMINING EFFICACY OF CHRONIC TREATMENT OF
ELN-0009-UA	20040907793	Feb-25-2003	85537	INFLAMATION ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-UY	27688	Feb-27-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF
ELN-0009-VE	2003-000630	Apr-22-2003	·······	INFLAMMATION ADMINISTRATION OF AGENTS FOR THE TREATMENT OF
ELN-0009-VN	1-2004-00960	Feb-25-2003		INFLAMMATION ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-WO	PCT/US2003/005421	Fcb-25-2003	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
LN-0009-ZA	2004/7406	Feb-25-2003	2004/7406	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0010-AR	P040100225	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-AU	2004207536	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-AU2	2004207535	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-AU-D1	2010212446	Jan-26-2004	2010212446	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS

Schedule B To Patent Assignment Page 9 OF 53 $\,$

Reference	Application No.	Application Date	Registration No.	Title
ELN-0010-AU2-	D1 2010201472	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-AU-D	2 2011201262	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-CA1	2,514,117	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-CA2	2,514,125	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-CL	0116-2004	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-CN	200480008089.0	Jan-26-2004	ZL200480008089.0	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-CO	05-084.319	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
LN-0010-EG	PCT 399/2005	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
.N-0010-EP	04705270.9	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
N-0010-EP-D1	11008463.9	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
V-0010-GC	GCC/P/2004/3259	Feb-28-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS

SCHEDULE B TO PATENT ASSIGNMENT PAGE 10 OF 53

Reference	Application No.	Application Date	Registration No.	Title
ELN-0010-IL	169770	Jan-26-2004	169770	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-IN	1994/CHENP/2005	Jan-26-2004	229369	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-JP	2006-503001	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-JP2	2006-502997	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF
ELN-0010-JP-D1	2011-121017	Jan-26-2004		REMYELINATING AGENTS COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-KR	10-2005-7013695	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-KR-D1	10-2012-7024847	Jan-26-2004	1260497	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-MX	PA/a/2005/007843	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-MX 1	MX/A/2005/007823	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
LN-0010-MX-D1	MX/a/2008/007693	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
.N-001-MX-D2	MX/a/2008/008267	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS

SCHEDULE B TO PATENT ASSIGNMENT PAGE 11 OF 53

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0010-MX-D3	MX/a/2010/001362	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-MY	PI 20040214	Feb-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-NO	20053920	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-PE	100			COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-PH	1-2005-501355	Jan-26-2004	1-2005-501355	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-PH-D1	1-2008-502081	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-PH-D2	1-2011-501872	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-PK	0040/2004	Jan-24-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
LN-0010-RU	2005126728	Jan-26-2004	2412721	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
LN-0010-SG	200504585-1	Jan-26-2004	P113988	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
.N-0010-SK	5064-2005	Jan-26-2004	•	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS

SCHEDULE B TO PATENT ASSIGNMENT PAGE 12 OF 53

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0010-TH	088245	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-TW	093101747	Jan-27-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-TW-D1	101146999	Jan-27-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-UA	200508278	Jan-26-2004	88604	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-UR	28170	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-VE	2004-000085	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-VN	1-2005-01185	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-WO	PCT/US2004/002039	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-ZA	2005/05869	Jan-26-2004	2005/05869	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS

Reference	Application No.	Application Date	Registration No.	Title
ELN-0011-AR	P040100411	Feb-10-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-AU	2004210679	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-AUD1	2010202254	Feb-09-2004	2010202254	IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-AUD2	2012202845	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF

Schedule B To Patent Assignment Page 13 OF 53 $\,$

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0011-CA	2,515,444	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF
ELN-0011-CL	0224-2004	Feb-09-2004	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	PREPARATION THEREOF IMMUNOGLOBULIN FORMULATION AND METHD OF
ELN-0011-CN	200480009441.2	Feb-09-2004	ZL200480009441.2	PREPARATION THEREOF IMMUNOGLOBULIN FORMULATION AND METHD OF
ELN-0011-CN-D1	201210292453.7	Feb-09-2004		PREPARATION THEREOF IMMUNOGLOBULIN FORMULATION AND METHD OF
ELN-0011-CO	05091313	Feb-09-2004		PREPARATION THEREOF IMMUNOGLOBULIN FORMULATION AND METHD OF
ELN-0011-EG	PCT 440/2005	Feb-09-2004		PREPARATION THEREOF IMMUNOGLOBULIN FORMULATION AND METHD OF
ELN-0011-EP	04709508.8	Feb-09-2004		PREPARATION THEREOF IMMUNOGLOBULIN FORMULATION AND METHD OF
ELN-0011-EP-D1	10005235,6	Feb-09-2004		PREPARATION THEREOF IMMUNOGLOBULIN FORMULATION AND METHO OF
ELN-0011-GC	GCC/P/2004/3212	Feb-09-2004		PREPARATION THEREOF IMMUNOGLOBULIN FORMULATION AND METHO OF
ELN-0011-HK	06111920.6	Feb-09-2004		PREPARATION THEREOF IMMUNOGLOBULIN FORMULATION AND METHO OF
ELN-0011-IL	170008	Feb-09-2004		PREPARATION THEREOF IMMUNOGLOBULIN FORMULATION AND METHD OF
ELN-0011-IN	2187/CHENP/2005	Feb-09-2004	252222	PREPARATION THEREOF IMMUNOGLOBULIN FORMULATION AND METHD OF
ELN-0011-JP	2006-503453	Feb-09-2004	4728948	PREPARATION THEREOF IMMUNOGLOBULIN FORMULATION AND METHD OF
ELN-0011-JP-D1	2010-277365	Feb-09-2004		PREPARATION THEREOF IMMUNOGLOBULIN FORMULATION AND METHD OF
ELN-0011-KR	10-2005-7014654	Feb-09-2004		PREPARATION THEREOF IMMUNOGLOBULIN FORMULATION AND METHD OF
ELN-0011-MX	PA/a/2005/008409	Feb-09-2004	302966	PREPARATION THEREOF IMMUNOGLOBULIN FORMULATION AND METHD OF
ELN-0011-MX-D1	MX/a/2012/010160	Feb-09-2004		PREPARATION THEREOF IMMUNOGLOBULIN FORMULATION AND METHD OF
ELN-0011-MY	PI 20040377	Feb-09-2004		PREPARATION THEREOF IMMUNOGLOBULIN FORMULATION AND METHD OF
LN-0011-NO	20054164	Feb-09-2004		PREPARATION THEREOF IMMUNOGLOBULIN FORMULATION AND METHD OF
LN-0011-PE	149/2004	Feb-10-2004	5147	PREPARATION THEREOF IMMUNOGLOBULIN FORMULATION AND METHD OF
LN-0011-PH	1-2005-501425	Feb-09-2004	1-2005-501425	PREPARATION THEREOF IMMUNOGLOBULIN FORMULATION AND METHD OF
LN-0011-PK	0078/04	Feb-09-2004	138744	PREPARATION THEREOF IMMUNOGLOBULIN FORMULATION AND METHD OF
LN-0011-RU	2005128280	Feb-09 -2 004	2358763	PREPARATION THEREOF IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF

SCHEDULE B TO PATENT ASSIGNMENT PAGE 14 OF 53

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0011-SG	200505045-5	Feb-09-2004	114176	IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-SK	PV 5067-2005	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-TH	088577	Feb-06-2004	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-TW	093103043	Feb-10-2004	1367766	IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-UA	200508632	Feb-()9-2004	82685	IMMUNOGLOBULIN FORMULATION AND METHD OF
ELN-0011-UY	28184	Feb-10-2003		PREPARATION THEREOF IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-VE	2004-000165	Feb-04-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-VN	1-2005-01248	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-WO	PCT/US2004/003873	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-ZA	2005/06159	Feb-09-2004	2005/06159	IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0012-AR	P050100431	Feb-04-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-AU	2005213324	Feb-03-2005	2005213324	METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-AU-D1	2011211351	Feb-03-2005	***************************************	METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-BR	PI0507451.7	Feb-03-2005	***************************************	METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-CA	2,555,365	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-CL	203-2005	Feb-02-2005	45.773	METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-CN	200580012148.6	Feb-03-2005	ZL200580012148.6	METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-EA	200601433	Feþ-03-2005	009873	METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-EP	05712339.0	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-EP-D1	11005763.5	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-GC	GCC/P/2005/4271	Feb-06-2005	annaimment ann ann ann ann ann ann ann ann ann a	METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE

Schedule B To Patent Assignment Page 15 OF 53

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0012-HK	07104930.8	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-ID	W-00200602188	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND
ELN-0012-IL	177201	Feb-03-2005		METASTATIC DISEASE METHODS AND COMPOSITIONS FOR TREATING TUMORS AND
ELN-0012-IN	3236/CHENP/2006	Feb-03-2005		METASTATIC DISEASE METHODS AND COMPOSITIONS FOR TREATING TUMORS AND
ELN-0012-JP	2006-552178	Feb-03-2005	4996261	METASTATIC DISEASE METHODS AND COMPOSITIONS FOR TREATING TUMORS AND
ELN-0012-KR	10-2006-7018079	Feb-03-2005		METASTATIC DISEASE METHODS AND COMPOSITIONS FOR TREATING TUMORS AND
ELN-0012-MX	PA/a/2006/008746	Feb-03-2005	286237	METASTATIC DISEASE METHODS AND COMPOSITIONS FOR TREATING TUMORS AND
ELN-0012-MY	PI 20050455	Feb-04-2005		METASTATIC DISEASE METHODS AND COMPOSITIONS FOR TREATING TUMORS AND
ELN-0012-NO	2006 3951	Feb-03-2005		METASTATIC DISEASE METHODS AND COMPOSITIONS FOR TREATING TUMORS AND
ELN-0012-NZ	548851	Feb-03-2005		METASTATIC DISEASE METHODS AND COMPOSITIONS FOR TREATING TUMORS AND
ELN-0012-NZ-D1	584288	Feb-03-2005	584288	METASTATIC DISEASE METHODS AND COMPOSITIONS FOR TREATING TUMORS AND
ELN-0012-NZ-D2	595379	Feb-03-2005		METASTATIC DISEASE METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-PE	129.2005	Feb-04-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-PH	1-2006-501514	Feb-03 - 2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-PK	0068/05	Feb-02-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-TH	097446	Feb-15-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-TW	094103833	Feb-05-2005	I375563	METHODS AND COMPOSITIONS FOR TREATING TUMORS AND
ELN-0012-UY	28741	Feb-04-2005		METASTATIC DISEASE METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-VE	2005-000205	Feb-04-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-WO	PCT/US2005/002860	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND
ELN-0012-ZA	2006/06557	Feb-03-2005	2006/06557	METASTATIC DISEASE METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE

SCHEDULE B TO PATENT ASSIGNMENT PAGE 16 OF 53

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0013 AU	2005232571	Mar-30-2005		STEROID SPARING AGENTS AND
Et at onto		minimum managa		METHODS OF USING THE SAME
ELN-0013-AU 2	2005231467	Apr-01-2005		STEROID SPARING AGENTS AND
ELN-0013-AU-D1	301101222			METHODS OF USING THE SAME
EEN-0013-AU-DI	2011213878	Mar-30-2005	2011213878	STEROID SPARING AGENTS AND
ELN-0013-CA 2	2,561,164	. Lancon manage	***************************************	METHODS OF USING THE SAME
		Apr-01-2005		STEROID SPARING AGENTS AND
ELN-0013-CA	2,561,364	Mar-30-2005		METHODS OF USING THE SAME
}	furummummummummum	QUUS-00-10101		STEROID SPARING AGENTS AND
ELN-0013-CL	742-2005	Mar-31-2005		METHODS OF USING THE SAME
TIM OG	fu	Jan 31-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-EP	05768245.2	Mar-30-2005		STEROID SPARING AGENTS AND
ELN-0013 EP2		yhmmunummunin yh	***************************************	METHODS OF USING THE SAME
ED14-0013 EBS	05763852.0	Apr-01-2005		STEROID SPARING AGENTS AND
ELN-0013-GC	COORTOO	Jummen mannen mannen men men men men men men men men men	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	METHODS OF USING THE SAME
2211-0013-0C	GCC/P/2005/4496	Apr-02-2005		STEROID SPARING AGENTS AND
ELN-0013-HK	07106887.6	<u> </u>		METHODS OF USING THE SAME
	······································	Mar-30-2005		STEROID SPARING AGENTS AND
ELN-0013 HK2	07110080.3	Mor 20 2005		METHODS OF USING THE SAME
		Mar-30-2005	-	STEROID SPARING AGENTS AND
ELN-0013-IL	178302	Mar-30-2005		METHODS OF USING THE SAME STEROID SPARING AGENTS AND
				METHODS OF USING THE SAME
ELN-0013-JP	2007-506536	Mar-30-2005		STEROID SPARING AGENTS AND
ELN-0013-JP 2			***************************************	METHODS OF USING THE SAME
ELN-0013-JP 2	2007-506344	Apr-01-2005		STEROID SPARING AGENTS AND
ELN-0013-JP-D1	2013-080823			METHODS OF USING THE SAME
	2015-080823	Mar-30-2005		STEROID SPARING AGENTS AND
ELN-0013-MY	PI 20051380	May 20 2005		METHODS OF USING THE SAME
	Janes	Mar-29-2005		STEROID SPARING AGENTS AND
ELN-0013-NO	2006 4979	Mar-30-2005		METHODS OF USING THE SAME STEROID SPARING AGENTS AND
***************************************			***************************************	METHODS OF USING THE SAME
ELN-0013-NZ	550040	Mar-30-2005	***************************************	STEROID SPARING AGENTS AND
ELN-0013-NZ-D1			***************************************	METHODS OF USING THE SAME
CC14-0012-MZ-D1	580057	Mar-30-2005		STEROID SPARING AGENTS AND
ELN-0013-NZ-D2	594476			METHODS OF USING THE SAME
······································	394470	Mar-30-2005		STEROID SPARING AGENTS AND
ELN-0013-TH	099245		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	METHODS OF USING THE SAME
***************************************		Mar-30-2005		STEROID SPARING AGENTS AND
ELN-0013-TW	094110385	Mar-31-2005	***************************************	METHODS OF USING THE SAME STEROID SPARING AGENTS AND
			***************************************	METHODS OF USING THE SAME
ELN-0013-UY	28838	Apr-01-2005		STEROID SPARING AGENTS AND
ZI NI 0012 110	7.00		***************************************	METHODS OF USING THE SAME
ELN-0013-WO	PCT/US2005/010848	Mar-30-2005		STEROID SPARING AGENTS AND
ELN-0013 WO2	DCT#162006/01122-	manamanamanaman kana		METHODS OF USING THE SAME
0015 WOZ	PCT/US2005/011307	Apr-01-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME

F&L Docket No.	Title	Country	Application Number	Appl Date	Patent Number	Grant Date
342837-1456	CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Argentina	P980103779	7/31/1998	Number	

Schedule B to Patent Assignment Page 17 OF 53

F&L Docket	Title	Country	Application Number	Appl Date	Patent Number	Grant Date
342837-1462	CARBAMYL COMPOUNDS WHICH	Australia	85849/98	7/31/1998		2/21/2002
	INHIBIT LEUKOCYTE					
	ADHESION			1		
	MEDIATED BY VLA-4					
342837-1463	CARBAMYL	Brazil	PI9811598-7	7/31/1998	+	
	COMPOUNDS WHICH		113011330-7	1/31/1998		
	INHIBIT LEUKOCYTE					
	ADHESION					
	MEDIATED BY VLA-4					
342837-1465		Canada	2290745	7/31/1998	 	
	COMPOUNDS WHICH		2230743	1/21/1998		
	INHIBIT LEUKOCYTE					
	ADHESION					
242027 4	MEDIATED BY VLA-4					
342837-1484	CARBAMYL	China P.R.	98807770.1	7/31/1998	ZL988077	8/27/2003
	COMPOUNDS WHICH			1,32,2330	70.01	0/2//2003
	INHIBIT LEUKOCYTE				75.51	
	ADHESION					
342837-1479	MEDIATED BY VLA-4			ļ		
342037-14/9	CARBAMYL	Germany	69824007.3	7/31/1998	EP100005	5/19/2004
	COMPOUNDS WHICH				1	3, 23, 2004
	INHIBIT LEUKOCYTE ADHESION				ļ	
	MEDIATED BY VLA-4					
342837-1466	CARBAMYLOXY	European				
	COMPOUNDS WHICH	Patent Office	98937052.3	7/31/1998	1000051	5/19/2004
	INHIBIT LEUKOCYTE	Faterit Office				
	ADHESION					
	MEDIATED BY VLA-4					
342837-1485	CARBAMYL	European	04011786.3	7/04/4500		
	COMPOUNDS	Patent Office	04011/86.3	7/31/1998	145532	9/1/2004
	WHICH INHIBIT	, and the office				
	LEUKOCYTE					
	ADHESION					
	MEDIATED BY VLA-4					
342837-1480	CARBAMYL	Spain	98937052.3	7/31/1998	10000E1	F (10/2004
	COMPOUNDS WHICH	•	20337032.5	//31/1990	1000051	5/19/2004
	INHIBIT LEUKOCYTE					
	ADHESION					
	MEDIATED BY VLA-4					
342837-1481	CARBAMYL	France	98937052.3	7/31/1998	100051	5/19/2004
	COMPOUNDS WHICH			, ,		3,13,2004
l	INHIBIT LEUKOCYTE					
	ADHESION					
1/12027 1/02	MEDIATED BY VLA-4					
342837-1482	CARBAMYL	United	98937052.3	7/31/1998	1000051	5/19/2004
	COMPOUNDS WHICH	Kingdom				
1	INHIBIT LEUKOCYTE					
ļ	ADHESION					
	MEDIATED BY VLA-4				ŀ	

SCHEDULE B TO PATENT ASSIGNMENT PAGE 18 OF 53

F&L Docke		Country	Application Number	Appl Date		Grant Dat
342837-14	67 CARBAMYŁ COMPOUNDS WHIC INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4		00105670.6	7/31/199	Number 98 1000051	
342837-14	86 CARBAMYL					
	COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4		05100583.8	7/31/199	98 1067131,	4/1/20
342837-146	COMPUONDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Hungary H	P0002035	7/31/199	8	
342837-148	CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VI A-4	Ireland	98937052.3	7/31/199	8 EP100005 1	5/19/200
342837-1469 342837-1490	9 CARBAMYL COMPUONDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Israel	133636	7/31/1998	3	
	ANTAGONISTS AND ANTI- INFLAMMATORY COMPOSITIONS THEROF	Japan	11-511273	7/31/1998		
342837-1470	COMPUONDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Japan	2000-505149	7/31/1998	4431717	1/8/2010
42837-1491	CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADEHSION MEDIATED BY VLA-4	Japan	2009-185319	8/7/2009		
42837-1478 42837-1471	CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	South Korea	10-2000- 7000952	7/31/1998	639055	10/20/2006
-2037-14/1	CARBAMYL COMPUONDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Mexico	000673	7/31/1998	225022	12/15/2004

SCHEDULE B TO PATENT ASSIGNMENT PAGE 19 OF 53

F&L Docket No.		Country	Application Number	Appl Date	Patent	Grant Dat
342837-147	3 CARBAMYL	Norway	20000413		Number	
	COMPUONDS WHICH	1	20000413	7/31/1998	·	
	INHIBIT LEUKOCYTE				1	
	ADHESION				1	
	MEDIATED BY VLA-4					1
342837-147	2 CARBAMYL	New Zealand	502578			
	COMPUONDS WHICH	I Lew Zealand	302578	7/31/1998		
	INHIBIT LEUKOCYTE					
	ADHESION					
	MEDIATED BY VLA-4				ļ	
342837-145	5 CARBAMYLOXY	P.C.T.	DOT/USASSA			
	COMPOUNDS WHICH	1	PCT/US1998/01	7/31/1998		
	INHIBIT LEUKOCYTE		5324			1
	ADHESION					
	MEDIATED BY VLA-4					
342837-1460	CARBAMYL	Philippin	1		L	
	COMPOUNDS WHICH	Philippines	1-1998-001943	7/31/1998	1-1998-	10/18/200
	INHIBIT LEUKOCYTE			1	01943	-3/20/
	ADHESION			1		
	MEDIATED BY VLA-4					
342837-1459	CARBAMYL	D-I:				1
	COMPOUNDS WHICH	Pakistan	790/98	7/30/1998		
	INHIBIT LEUKOCYTE]		
1	ADHESION					
	MEDIATED BY VLA-4		1			
342837-1474	CARBAMYL	Poland				
	COMPUONDS WHICH	roland	P-338521	7/31/1998		
	INHIBIT LEUKOCYTE					
	ADHESION					
	MEDIATED BY VLA-4			i		
42837-1475	CARBAMYL	Russian	200010			
	COMPOUNDS		2000104850	7/31/1998	2220964	1/10/2004
	WHICH INHIBIT	Federation				. , ===
	LEUKOCYTE			1	ļ	
	ADHESION				1	
	MEDIATED BY VLA-4					
42837-1476	CARBAMYL	Singapore	0000107			
	COMPOUNDS WHICH	Singapore	9906195-4	7/31/1998	69767	3/22/2002
	INHIBIT LEUKOCYTE					
	ADHESION					
	MEDIATED BY VLA-4				1	
12837-1489		P.C.T.	DCT/UC1000/04	7/2//		
	ANTAGONISTS AND		PCT/US1998/01	7/31/1998		
ļ	ANTI-	Ì	5958			
1	INFLAMMATORY					
-	COMPOSITIONS					
	THEROF					
2837-1457	CARRIAN	Venezuela	1000 001500			
	COMPOUNDS WHICH	A CLICANEIG	1998-001683	7/30/1998		
1	INHIBIT LEUKOCYTE				}	
	ADHESION			1		
	MEDIATED BY VLA-4					
	DI VLA-4			1	1	

SCHEDULE B TO PATENT ASSIGNMENT PAGE 20 OF 53

F&L Docket		Country	Application Number	Appl Date	1	Grant Dat
342837-146	CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4		98/6830	7/30/199	Number 98	
342837-147	7 CARBAMYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	South Africa				
342837-155	5 Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Argentina	P000100287	1/24/200	0	
342837-2403 342837-1561	Inhibit Leukocyte Adhesion Mediated by VLA-4	Argentina	P000100286	1/24/2000	O AR 033643	11/24/201
	which Treat VLA-4 Related Disorders	Australia	34724/00	1/21/2000	773538	9/9/2004
342837-1562	WHICH TREAT VLA-4 RELATED DISORDERS	Brazil	0007663-5	1/21/2000		
342837-2409	Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Canada	2359113	1/21/2000		
342837-1563	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Canada	2359115	1/21/2000	2359115	6/21/2011
342837-1587	ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS	Switzerland	00913245.7	1/21/2000	1144388	1/13/2010
342837-2404	COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Chile	141-2000	1/24/2000		
	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Chile	140-2000	1/24/2000	48387	4/19/2012
	Acyl Derivatives Which Treat VLA-4 Related Disorders	China P.R.	00804078.8	1/21/2000	ZL008040 78.8	9/28/2005

SCHEDULE B TO PATENT ASSIGNMENT PAGE 21 OF 53

F&L Docket No.	Title	Country	Application Number	Appl Date	Patent	Grant Date
342837-2410	Inhibit Leukocyte Adhesion Mediated by VLA-4	China P.R.	00804498.8	1/21/200	Number 0	
342837-1565	Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Czech Republic	PV2001-2361	1/21/200	0	
342837-1588	WHICH TREAT VLA-4 RELATED DISORDERS	Germany	00913245.7	1/21/2000	1144388	1/13/201
342837-1589	WHICH TREAT VLA-4 RELATED DISORDERS	Denmark	00913245,7	1/21/2000	1144388	1/13/201
342837-1566 342837-1567	HETERCOYCLIC AND ARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Eurasian Pat. Convention	200100797	1/21/2000	006301	10/27/2009
	ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS	European Patent Office	00913245.7	1/21/2000	1144388	1/13/2010
342837-2411	Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	European Patent Office	00904487.6	1/21/2000	1144384	10/31/2007
342837-2417	Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	United Kingdom	00904487.6	1/21/2000	1144384	10/31/2007
342837-1590	ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS	Spain	00913245.7	1/21/2000	1144388	1/13/2010
342837-1591	ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS	France	00913245.7	1/21/2000	1144388	1/13/2010
42837-1592	ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS	United Kingdom	00913245.7	1/21/2000	1144388	1/13/2010
	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Hong Kong	02106386.7	1/21/2000		
	ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS	Hong Kong	02107038.7	1/21/2000	1046132	5/4/2006

SCHEDULE B TO PATENT ASSIGNMENT PAGE 22 OF 53

F&L Docket No.		Country	Application Number	Appl Date	1	Grant Da
342837-241	4 Compounds Which	Hong Kong			Number	
	Inhibit Leukocyte	110.18 110118	02106386.7	1/21/20	00	
	Adhesion Mediated					
	by VLA-4					
342837-156		Hungary				
	Heterocyclic and Ary	i Hungary	P0201213	1/21/200	00	
	Compounds Which	'				
	Inhibit Leukocyte			l		
	Adhesion Mediated					
	by VLA-4				Í	
342837-159	3 ACYL DERIVATIVES					j
	WHICH TREAT VLA-4	Ireland	00913245.7	1/21/200	00 1144388	1/42/55
	RELATED DISORDERS			-/21/200	1144388	1/13/20
342837-2418	RELATED DISORDERS					
- 12007 2410	I THE GRANGS AND THE	Ireland	00904487.6	1/21/200	0 1144384	
	Inhibit Leukocyte			1/21/200	1144384	10/31/200
	Adhesion Mediated					
342837-1569	by VLA-4		_	1		
342037-1309		Israel	143929	1/21/2000	0 143929	
	WHICH TREAT VLA-4			1/21/2000	143929	6/21/200
342837-1570	RELATED DISORDERS				ł	
342037-15/0	i i i i i i i i i i i i i i i i i i i	India	IN/PCT/2001/0	1/21/2000		
	Heterocyclic and Aryl		0984/CHE	1/21/2000	'	1
	Compounds Which		1 1, 5112			
	Inhibit Leukocyte			1		
	Adhesion Mediated					
242027.2	by VLA-4					
342837-2412	Compounds Which	Japan	2000-594785	1/24/2000	 	
	Inhibit Leukocyte		2000 554765	1/21/2000	1	
	Adhesion Mediated					
	by VLA-4					1
342837-1571	ACYL DERIVATIVES	South Korea	2001-7009075	<u> </u>		
	WHICH TREAT VLA-4	uni Norca	2001-7003075	1/21/2000	711840	4/19/2007
	RELATED DISORDERS			1		
342837-1573	ACYL DERIVATIVES	Mexico	Ba / / / / / / / / / / / / / / / / / / /	ļ		
	WHICH TREAT VLA-4	MEXICO	PA/a/2001/007	1/21/2000	244336	3/22/2007
	RELATED DISORDERS		335			,
42837-2413	Compounds Which	Movies				
	Inhibit Leukocyte	Mexico	PA/a/2001/007	1/21/2000	223125	9/29/2004
ļ	Adhesion Mediated		396	1		-, -5, 2004
l	by VLA-4					
42837-2415	Compounds Which	N.A.				
	Inhibit Leukocyte	Mexico	PA/a/2004/005	1/21/2000	254447	2/11/2008
1	Adhesion Mediated		706			. ,
1	by VLA-4					
12837-1594	ACM DEDUCE	Notherda				
	WHICH TREAT VLA-4	Netherlands	00913245.7	1/21/2000	1144388	1/13/2010
Ĭ	RELATED DISORDERS					-, -5, 2010
					1	
		Norway	20013600	1/21/2000	323373	4/16/2007
1	Heterocyclic and Aryl					→/ ±0/ 200 /
	Compounds Which				1	1
1	Inhibit Leukocyte					I
	Adhesion Mediated				1	1
	by VLA-4		i .	1		i

SCHEDULE B TO PATENT ASSIGNMENT PAGE 23 OF 53

F&L Docket No.	Title	Country	Application Number	Appl Date	Patent Number	Grant Date
342837-1574	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	New Zealand	512563	1/21/2000		
342837-1581	Acyl Derivatives Which Treat VLA-4 Related Disorders	New Zealand	529822	1/21/2000	529822	3/9/2006
342837-1554	WHICH TREAT VLA-4 RELATED DISORDERS	P.C.T.	PCT/US2000/00 1686	1/21/2000		
342837-2402	Inhibit Leukocyte Adhesion Mediated by VLA-4	P.C.T.	PCT/US2000/00 1540	1/21/2000		
342837-1557	Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Philippines	1-2000-00159	1/21/2000	1-2000- 00159	5/26/2005
342837-2405	Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Philippines	1-2000-00160	1/21/2000		
342837-1558	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Pakistan	0047/2000	1/22/2000	140939	12/16/2011
342837-2406	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Pakistan	48/2000	1/22/2000		
342837-1576	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Poland	P-350050	1/21/2000		
342837-1583	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Russian Federation	200100797	1/21/2000	006301	10/27/2005
342837-1595	ACYL DERIVATIVES . WHICH TREAT VLA-4 RELATED DISORDERS	Sweden	00913245.7	1/21/2000	1144388	1/13/2010

SCHEDULE B TO PATENT ASSIGNMENT PAGE 24 OF 53

F&L Docket		Country	Application Number	Appl Date	1	Grant Da
342837-157	Heterocyclic and Ary Compounds Which Inhibit Leukocyte Adhesion Mediated	Singapore	200104173-0	1/21/200	Number 00	
342837-155	by VLA-4 9 Heteroaryl,					
	Heterocyclic and Ary Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Taiwan	089101088	1/24/200	0 1239954	9/21/20
342837-2407	7 Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Taiwan	89101087	1/24/2000	0	
342837-1560	Heteroaryl, Heterocyclic and Aryl Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Venezuela	2000-000165	1/24/2000		
342837-2408	Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Venezuela	2000-000163	1/24/2000		
342837-1578	ACYL DERIVATIVES WHICH TREAT VLA 4 RELATED DISORDERS	South Africa	2001/05314	1/21/2000	2001/053 14	6/25/2003
342837-1578	ACYL DERIVATIVES WHICH TREAT VLA 4 RELATED DISORDERS	South Africa	2001/05314	1/21/2000	2001/053 14	6/25/2003
42837-1653	FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Argentina	P000100266	1/21/2000		
	FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Australia	25135/00	1/21/2000	769741	5/27/2004

SCHEDULE B TO PATENT ASSIGNMENT PAGE 25 OF 53

F&L Docket No.		Country	Application	Appl Date	e Patent	Grant Da
342837-166	0 FUSED RING	Canada	Number		Number	
	HETEROARYL AND	Carraua	2359112	1/21/20	00	
	HETEROCYCLIC				1	
	COMPOUNDS WHICH	,				
	INHIBIT LEUKOCYTE	1				1
	ADHESION					
	MEDIATED BY VLA-4					
342837-165	4 Fused Ring					
	1	Chile	128-2000	1/21/200	20	
	Heteroaryl and			1/21/200	,0	j
	Heterocyclic			İ		
	Compounds Which					
	Inhibit Leukocyte					1
242027 455	Adhesion by VLA-4					
342837-1661	FUSED RING	China P.R.	00802933.4			
	HETEROARYL AND		00002933.4	1/21/200	0	
	HETEROCYCLIC		1		ĺ	1
	COMPOUNDS WHICH			1		
	INHIBIT LEUKOCYTE	1				
	ADHESION					
	MEDIATED BY VLA-4				1	1
342837-1662	FUSED RING	European				
	HETEROARYL AND	Patent Office	00903379.6	1/21/2000)	
	HETEROCYCLIC	, atom office		ĺ		
	COMPOUNDS WHICH					
	INHIBIT LEUKOCYTE					
	ADHESION					
	MEDIATED BY VLA-4					
42837-1668	FUSED RING	Hone K			1	
	HETEROARYL AND	Hong Kong	02105462.6	1/21/2000		
	HETEROCYCLIC					
	COMPOUNDS WHICH				1 1	
	INHIBIT LEUKOCYTE				1	
	ADHESION				1	
	MEDIATED BY VLA-4					
12837-1663	ELICED DINIO	1		1		
	HETEROARYL AND	Israel	143928	1/21/2000	143928	5/12/2007
ĺ	HETEROCYCLIC				= .5526	5/12/2007
1	COMPOUNDS					
	COMPOUNDS WHICH				}	
1	INHIBIT LEUKOCYTE				1	
	ADHESION				ļ	
2837-1665	MEDIATED BY VLA-4					
4	FUSED RING	Mexico	PA/a/2001/007	1/21/2000	223926	14/0/
1	HETEROARYL AND		330	-,, 2000	443940	11/3/2004
	HETEROCYCLIC			1		
1:	COMPOUNDS WHICH					
1 '	NHIBIT LEUKOCYTE			Ī		
	ADHESION			1		
	MEDIATED BY VLA-4					

SCHEDULE B TO PATENT ASSIGNMENT PAGE 26 OF 53

F&L Docket		Country	Application Number	Appl Date		Grant Dat
342837-166	6 FUSED RING	New Zealand			Number	
	HETEROARYL AND	THE W Zealand	512565	1/21/200	0 512565	3/29/200
	HETEROCYCLIC					, -, -,
	COMPOUNDS WHICH	.		1		
l	INHIBIT LEUKOCYTE	'				
	ADHESION				- 1	
	MEDIATED BY VLA-4					
342837-1669	FUSED RING					1
	HETEROARYL AND	New Zealand	528904	1/21/200	0	
	HETEROCYCLIC					
	COMPOUNDS WHICH	.		1		
	INHIBIT LEUKOCYTE	1				
	ADHESION					1
342837-1652	MEDIATED BY VLA-4					
	1 . SOLD WING	P.C.T.	PCT/US2000/00	0 1/21/2000	,	
	HETEROARYL AND		1536	1/21/2000	'	1
	HETEROCYCLIC			1		1
	COMPOUNDS WHICH					
	INHIBIT LEUKOCYTE				1	
	ADHESION	ŀ				
342837-1655	MEDIATED BY VLA-4				İ	
342037-1033	FUSED RING	Philippines	1-2000-00158	1/21/2000		
	HETEROARYL AND			1/21/2000	1	
	HETEROCYCLIC			1	1	
	COMPOUNDS WHICH	i		į		l
	INHIBIT LEUKOCYTE					
	ADHESION					
342837-1656	MEDIATED BY VLA-4				1	
42037-1656	FUSED RING	Pakistan	0045/2000	1/21/2000		
	HETEROARYL AND	٠	10,2000	1/21/2000		
	HETEROCYCLIC					
	COMPOUNDS WHICH					
1	INHIBIT LEUKOCYTE			1		
1	ADHESION		1		f	
12027 1655	MEDIATED BY VLA-4]	
12837-1657	FUSED RING	Taiwan	089100997	1/21/2000	All age	
	HETEROARYL AND			1/21/2000	NI-203589	6/21/2004
	HETEROCYCLIC					
	COMPOUNDS WHICH					
1	INHIBIT LEUKOCYTE				1	İ
	ADHESION		ļ			
	MEDIATED BY VLA-4					
	FUSED RING	Venezuela	2000-000151	1/21/2000		
	HETEROARYL AND		720 000131	1/21/2000		
	HETEROCYCLIC	1	1		1	
•	COMPOUNDS WHICH			ļ	1	
	NHIBIT LEUKOCYTE	i			1	1
A	ADHESION			ł		1
N	MEDIATED BY VLA-4		1		1	

SCHEDULE B TO PATENT ASSIGNMENT PAGE 27 OF 53

F&L Docke No.		Country	Application	Appl Date		Grant Dat
342837-16	. ages mild	South Africa	Number 20015312	1/24/22	Number	
	HETEROARYL AND		20013312	1/21/200	,	12/24/20
1	HETEROCYCLIC				12	
	COMPOUNDS WHIC	CH	1			
1	INHIBIT LEUKOCYTE					
	ADHESION				- }	
	MEDIATED BY VLA-2	1				
342837-215		Canada	2361162			
	ACID DERIVATIVES		2301102	2/28/200	00	
	USEFUL AS ALPHA 4					
	BETA 7-RECEPTOR					
-	ANTAGONISTS					
342837-215	I work a controduce the	Germany	00910364.9			
1	Acid Derivatives-	,	00310304.9	2/28/200	1	4/14/200
	Alpha 4 Beta 7	j		ļ	-4	į
	Receptor Antagonist	s				
342837-215	5 ALPHA-	European	00910364.9			
	AMINOACETIC ACID	Patent Office	00910364.9	2/28/2000	1161416	4/14/200
	DERIVATIVES USEFUL	.		1		
	AS ALPHA 4 BETA 7 -				l i	
	RECEPTOR					
2420-	ANTAGONISTS					
342837-2156	I where the sum of ceffe	France	00910364.9	2/20/2000		
	Acid Derivatives-		00310304.9	2/28/2000	1161416	4/14/200
	Alpha 4 Beta 7					•
242027 2455	Receptor Antagonists	_				
342837-2158	- where continuous effic	United	00910364.9	2/28/2000	1151115	
	Acid Derivatives-	Kingdom		2/20/2000	1161416	4/14/2004
	Alpha 4 Beta 7					
242027 2450	Receptor Antagonists				1	
342837-2159	Alpha Aminoacetic	Ireland	00910364.9	2/28/2000	1161416	
	Acid Derivatives-			2/28/2000	1161416	4/14/2004
	Alpha 4 Beta 7				1	
342837-2153	Receptor Antagonists					
942837-2153	Alpha Aminoacetic	Japan	2000-602202	2/28/2000	 	
	Acid Derivatives-		1	2/20/2000		
	Alpha 4 Beta 7					
342837-2152	Receptor Antagonists					
42637-2152	Alpha-Aminoacetic	P.C.T.	PCT/US2000/00	2/28/2000		
	Acid Derivatives		4960	2/20/2000		
	Useful As Alpha 4					
	Beta 7 - Receptor					
42837-1572	Antagonists					
72037-1372	ACYL DERIVATIVES	Japan	2000-594788	1/21/2000	4754693	6/3/2011
	WHICH TREAT VLA-4					0/3/2011
42837-1596	RELATED DISORDERS					
05/-1390	Heteroaryl,	Japan	2011-11456	1/21/2000		
	Heterocyclic and Aryl	t.				
I	Compounds Which					
	Inhibit Leukocyte Adhesion Mediated			1		
	by VLA-4					
	~ y V L/1-4					1

SCHEDULE B TO PATENT ASSIGNMENT PAGE 28 OF 53

F&L Docket No.	Title	Country	Application Number	Appl Date	Patent	Grant Dat
342837-185	Alpha Amino Acid Derivatives — Inhibitors of	P.C.T.	PCT/US2001/02 3075	7/20/2001	Number L	
	Leukocyte Adhesion					
242027 427	Mediated by VLA-4]	
342837-195	1 3-(Heteroaryl)alanine Derivatives Inhibitors of Leukocyte Adhesion Mediated by VLA-4	P.C.T.	PCT/US2001/02 3097	7/20/2001		
342837-1378	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	United Arab Emirates	471/2004	5/27/2003		
342837-1600	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Armenia	200401562	5/27/2003	008256	4/27/200
342837-1353	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Argentina	P030104212	11/14/200		
342837-1357	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Australia	2003240823	5/27/2003	20032408 23	5/21/2009
342837-1601	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Azerbaijan	200401562	5/27/2003	008256	4/27/2007
342837-1358	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Brazil	PI0308881-2	5/27/2003		
	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Belarus	200401562	5/27/2003	008256	4/27/2007

SCHEDULE B TO PATENT ASSIGNMENT PAGE 29 OF 53

F&L Docket No.	Title	Country	Application	Appi Date	Patent	Grant Dat
342837-135	9 HETEROCYCLIC		Number		Number	Grant Dat
	COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION	Canada	2481926	5/27/200		
	MEDIATED BY ALPHA					
	4 INTEGRINS					
342837-138	8 HETEROCYCLIC	Savita and and				
	COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS		03731419.2	5/27/200	1507775	12/31/200
342837-1360	HETEROCYCLIC	China P.R.	02014740			
	COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA		03811548.4	5/27/200	3 ZL038115 48.4	5/9/200
3/12927 1201	4 INTEGRINS				}	
342837-1381	N-[2-N`, N`- DIETHYLAMINOSULF ONYLPHENLYPYRIMI	Colombia	03-103.979A	11/25/200	l l	8/28/2009
	DIN-4-YL] P-			1		
	CARBOMYLOXY-					
	PHENYLALANINE					
	DERIVATIVE				1	
	COMPOUNDS					
342837-1354	HETEROCYCLIC	Colombia	03 103 070			
	COMPOUNDS WHICH	Giannala	03-103.979	11/25/200	29022	8/28/2009
	INHIBIT LEUKOCYTE		İ	3		
	ADHESION				1	
	MEDIATED BY ALPHA					j
142027 4000	4 INTEGRINS					ļ
42837-1382	HETEROCYCLIC	Germany	03731419.2	5/27/2003	60325583.	
	COMPOUNDS WHICH			3/2//2003	3-08	12/31/2008
	INHIBIT LEUKOCYTE				3-08	
	ADHESION					
	MEDIATED BY ALPHA					
42837-1389	4 INTEGRINS		`			
12037-1309	HETEROCYCLIC	Denmark	03731419.2	5/27/2003	1507775	12/31/2008
	COMPOUNDS WHICH INHIBIT LEUKOCYTE					12/31/2008
ĺ	ADHESION					
	MEDIATED BY ALPHA				1	
	4 INTEGRINS					
		urasian Pat.	200404562			
		Convention	200401562	5/27/2003	008256	1/15/2007
1	INHIBIT LEUKOCYTE					
	ADHESION				1	1
	MEDIATED BY ALPHA			1		1
	4 INTEGRINS					

SCHEDULE B TO PATENT ASSIGNMENT PAGE 30 OF 53 $\,$

F&L Dock		Title	Country	1	Application	Appl Da	ate	Patent	Grant Dat
342837-1		HETEROCYCLIC COMPOUNDS WHI	Ecuado:	r	Number 04-5425-PC			Number Pl 2011-	
	- ∤.	INHIBIT LEUKOCYT ADHESION	1					2058	1,20,20
	1 4	MEDIATED BY ALPI 1 INTEGRINS	AH						
342837-13	379 1	HETEROCYCLIC	Egypt		120/2004				
		COMPOUNDS WHIC NHIBIT LEUKOCYTE NDHESION	CH		120/2004	5/27/20	003		
	١	MEDIATED BY ALPH INTEGRINS	А						
342837-13	75 H	ETEROCYCLIC	European						
	0	OMPOUNDS WHIC IHIBIT LEUKOCYTE	H Patent Of	fice	03731419.2	5/27/20	03 1	507775	12/31/2008
	AI	DHESION EDIATED BY ALPHA	ŀ						
342837-138	41	NTEGRINS							
- 100, 150	CC	TEROCYCLIC MPOUNDS WHICH	Spain		03731419.2	5/27/200	3 15	507775	12/31/2008
	INI	HIBIT LEUKOCYTE HESION							12/31/2008
-	ME 4 II	DIATED BY ALPHA		1					
342837-1384	HE	TEROCYCLIC	France		03731419.2				
	INH	MPOUNDS WHICH IBIT LEUKOCYTE			00701415.2	5/27/2003	3 150	07775	12/31/2008
	ADF	HESION DIATED BY ALPHA							
342837-1385	4 IN	TEGRINS			•				
	COM	EROCYCLIC 1POUNDS WHICH	United Kingdom		03731419.2	5/27/2003	150	7775	12/31/2008
	INHI	BIT LEUKOCYTE ESION	·····guoiii						12/31/2008
	MED	IATED BY ALPHA EGRINS							
42837-1380	HETE	ROCYCLIC POUNDS WHICH	Hong Kong	0	5106028.8	5/27/2003	1073	1500	
	INHIE	IT LEUKOCYTE			i	3/2//2003	1072	608	8/14/2009
	ADHE MEDI	ATED BY ALPHA							
2837-1363	4 INTE	ROCYCLIC	Indonesia						
	COMP INHIBI	OUNDS WHICH	muonesia	00	- 200402607	5/27/2003	ID001 5	914	4/18/2007
1	ADHES MEDIA	SION TED BY ALPHA							
	4 INTE	GRINS			1			- 1	1

SCHEDULE B TO PATENT ASSIGNMENT PAGE 31 OF 53

F&L Docket No.	Title	Country	Application	Appl Date	Patent	Grant Date
342837-1386	HETEROCYCLIC	111	Number		Number	
0.12337.1330	COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Ireland	03731419.2	5/27/2003	1507775	12/31/2008
342837-1364	COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Israel	164225	5/27/2003	164225	3/1/2011
342837-1362	COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	India	1535/KOLNP/2 004	5/27/2003	215531	2/27/2008
342837-1387	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Italy	03731419.2	5/27/2003	1507775	12/31/2008
342837-1365	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Japan	2004-507466	5/27/2003	4469715	3/5/2010
342837-1603	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Kyrgyzstan	200401562	5/27/2003	008256	4/27/2007
342837-1366	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	South Korea	2004-7018173	5/27/2003	10- 0978832	8/24/2010
342837-1604	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Kazakhstan	200401562	5/27/2003	008256	4/27/2007

SCHEDULE B TO PATENT ASSIGNMENT PAGE 32 OF 53

F&L Docket No.	Title	Country	Application Number	Appl Date	Patent	Grant Date
342837-5089	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Kazakhstan	200801906	2/26/2007	Number 017110	9/28/2012
342837-5090	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Kyrgyzstan	200801906	2/26/2007	017110	9/28/2012
342837-5091	Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Moldova	200801906	2/26/2007	017110	9/28/2012
342837-5092	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Russian Federation	200801906	2/26/2007	017110	9/28/2012
342837-5093	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Tajikistan	200801906	2/26/2007	017110	9/28/2012
342837-5094	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Turkmenistan	200801906	2/26/2007	017110	9/28/2012
342837-5077	PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Ecuador	SP-08-8701	2/26/2007		
342837-5078	PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Egypt	1394/2008	8/18/2008		

Schedule B to Patent Assignment Page 41 OF 53

F&L Docket No.	Title	Country	Application Number	Appl Date	Patent	Grant Date
342837-506	7 PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	European Patent Office	07757498.6	2/26/2007	Number	
342837-5084	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Hong Kong	09104919.1	2/26/2007		
342837-5068	Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Israel	193425	2/26/2007		
342837-5069	PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	India	3409/KOLNP/2 008	2/26/2007		
342837-5079	PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Japan	2008-556582	2/26/2007	5135235	11/16/2012
342837-5070	PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	South Korea	10-2008- 7023333	2/26/2007		
342837-5081	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Morocco	31231	2/26/2007	30318	4/1/2009
42837-5071	PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Mexico	MX/a/2008/010 988	2/26/2007	286803	5/20/2011

SCHEDULE B TO PATENT ASSIGNMENT PAGE 42 OF 53

F&L Docket No.	Title	Country	Application Number	Appl Date	Patent Number	Grant Date
342837-5080	PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Malaysia	PI 20083293	2/26/2007		
342837-5072	SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Norway	20083743	2/26/2007		
342837-5073	Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	New Zealand	570679	2/26/2007		
342837-5060	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	P.C.T.	PCT/US2007/06 2824	2/26/2007		
342837-5083	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Philippines	1-2008-501917	2/26/2007		
342837-5082	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Singapore	200806100-4	2/26/2007	145322	3/15/2011
342837-5062	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Taiwan	096106544	2/26/2007		
342837-5074	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	South Africa	2008/07188	2/26/2007	2008/071 88	1/27/2010
	PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS	P.C.T.	PCT/US2010/03 2632	4/27/2010		

SCHEDULE B TO PATENT ASSIGNMENT PAGE 43 OF 53

F&L Docket No.	Title	Country	Application Number	Appl Date	Patent Number	Grant Date
342837-5161	ANTAGONISTS OF ALPHA-4 INTEGRINS	Australia	2010241742	4/27/2010	Number	
342837-5162	ANTAGONISTS OF ALPHA-4 INTEGRINS	Brazil	PI1015259-8	4/27/2010		
342837-5163	ANTAGONISTS OF ALPHA-4 INTEGRINS	Canada	2760151	4/27/2010		
342837-5164	ANTAGONISTS OF ALPHA-4 INTEGRINS	China P.R.	201080027375. 7	4/27/2010		
342837-5165	ANTAGONISTS OF ALPHA-4 INTEGRINS	European Patent Office	10719684.2	4/27/2010		
342837-5166	ANTAGONISTS OF ALPHA-4 INTEGRINS	India	4416/KOLNP/2 011	4/27/2010		
342837-5167	PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS	Israel	215956	4/27/2010		
342837-5168	PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS	Japan	2012-507475	4/27/2010		
342837-5169	PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS	Mexico	MX/a/2011/011 326	4/27/2010		
342837-5170	PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS	Singapore	201107840-9	4/27/2010		
342837-1152	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Argentina	P980103778	7/30/1998		
342837-1158	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Australia	86611/98	7/30/1998	756696	5/8/2003
342837-1159	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Brazil	PI9812114-6	7/30/1998		

SCHEDULE B TO PATENT ASSIGNMENT PAGE 44 OF 53

F&L Docket No.	Title	Country	Application Number	Appl Date	Patent Number	Grant Date
342837-1160	Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Canada	2290747	7/30/1998	Number	
342837-1161	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	China P.R.	98807753.1	7/30/1998	ZL988077 53.1	1/7/2004
342837-1162	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	European Patent Office	98937990.4	7/30/1998		
342837-1163	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Hungary	P0004259	7/30/1998		
342837-1173	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Hong Kong	00105671.5	7/30/1998		·
342837-1164	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Israel _.	133640	7/30/1998		
342837-1165	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Japan	2000-505186	7/30/1998		
342837-1172	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	South Korea	10-2000- 7000991	7/30/1998		

SCHEDULE B TO PATENT ASSIGNMENT PAGE 45 OF 53

F&L Docket	Title	Country	Application	Appl Date	Patent	Grant Date
342837-1166	C. L. Liu		Number		Number	
	Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Mexico	000711	7/30/1998		
342837-1168	Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Norway	20000450	7/30/1998		
342837-1167	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	New Zealand	502582	7/30/1998	502582	11/4/2002
342837-1151	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	P.C.T.	PCT/US1998/01 5313	7/30/1998		
342837-1153	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Philippines	1998-001905	7/24/1998	1-1998- 01905	3/24/2005
342837-1154	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Pakistan	0792/98	7/30/1998	**	
342837-1169	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Poland	P-338423	7/30/1998		
342837-1174	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Poland	P-375244	7/30/1998		

SCHEDULE B TO PATENT ASSIGNMENT PAGE 46 OF 53

$\underline{Schedule\;B}$

F&L Docket No.	Title	Country	Application Number	Appl Date	Patent	Grant Date
342837-1170	Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Russian Federation	2000104853	7/30/1998	Number	
342837-1171	Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Singapore	9906211-9	7/30/1998	69778	4/10/2002
342837-1155	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Taiwan	087112638	7/31/1998	NI-178968	6/1/2003
342837-1156	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Venezuela	1998-001702	7/31/1998		
342837-1157	Substituted Phenylalanine Type Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	South Africa	98/6827	7/30/1998	98/6827	7/26/2000

MBHB Case No.	Application No. / Patent No.	Filing/Issued Date	Title
05 440 1540 145		(mm/dd/yyyy)	
05-119-WO-KR	KR 10-2007-7029811	12/20/2007	Imidazolone Phenylalanine Derivatives As VLA-4 Antagonists
05-119-WO	PCT/US2006//19708	05/22/2006	Imidazolone Phenylalanine Derivatives As VLA-4 Antagonists
05-051-B1	CA2554188	01/24/2005	Polyethylene Glycol Conjugates Of Heterocycloalkyl Carboxamido Propanoic Acids
05-051-B2	EP05712086.7	01/24/5005	Polyethylene Glycol Conjugates Of Heterocycloalkyl Carboxamido Propanoic Acids
05-051-B3	JP2006-551442	01/24/2005	Polyethylene Glycol Conjugates Of Heterocycloalkyl Carboxamido Propanoic Acids
05-051-B	PCT/US2005/002478	01/24/2005	Polyethylene Glycol Conjugates Of Heterocycloalkyl Carboxamido Propanoic Acids
05-553-WO	PCT/US2006/26292	07/07/2006	Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds

SCHEDULE B TO PATENT ASSIGNMENT PAGE 47 OF 53

MBHB Case No.	Application No. / Patent No.	Filing/Issued	Title
	Tatent 140.	Date	
05-881-WO-AU	AU2007253717	(mm/dd/yyyy) 05/22/2007	
	1.00001200111	05/22/2007	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food
05-881-WO-BR	BR PI07I2013-3	05/22/2007	Additive Compounds
05 004 14/0		03/22/2007	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food Additive Compounds
05-881-WO-CA	CA2651500	05/22/2007	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food
05-881-WO-CN	CN2007800278I 0.4	0.7/0.7	Additive Compounds
	01420078002781 0.4	05/22/2007	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food
05-881-WO-CO	C008.135.138	05/22/2007	Additive Compounds
05.004.1115		00/22/2007	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food Additive Compounds
05-881-WO-ES	EA20087056I	05/22/2007	Preparation Of Polymer Conjugates Of
05-881-WO-EP	ED07700000		Inerapeutic, Agricultural, And Food Additive Compounds
00 00 •••O-Li	EP07762290.0	05/22/2007	Preparation Of Polymer Conjugates Of
			Therapeutic, Agricultural, And Food
05-881-CN-HK	HK091082I8.0	05/22/2007	Additive Compounds
		03/22/2007	Preparation Of Polymer Conjugates Of
)5 DO4 (MO 15		j	Therapeutic, Agricultural, And Food Additive Compounds
05-881-WO-ID	ID W-00200803766	05/22/2007	Preparation Of Polymer Conjugates Of
			Therapeutic, Agricultural, And Food
05-881-WO-IL	11 105147		Additive Compounds
33-00 1-VVO-IL	IL195147	05/22/2007	Preparation Of Polymer Conjugates Of
			Therapeutic, Agricultural, And Food
)5-881-WO-IN	IN4581 /KOLNP/2008	05/00/0007	Additive Compounds
	11 1001 /1COEM 72000	05/22/2007	Preparation Of Polymer Conjugates Of
			Therapeutic, Agricultural, And Food
5-881-WO-JP	JP2009-512263	05/22/2007	Additive Compounds
		70.22.2007	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food
5 004 1140			Additive Compounds
5-881-WO-KR	KR I 0-2008-7030834	05/22/2007	Preparation Of Polymer Conjugates Of
	İ		Therapeutic, Agricultural, And Food
5-881-WO-MX	140// (0000 to //		Additive Compounds
3-60 I-44O-MX	MX/a/2008/0I4520	05/22/2007	Preparation Of Polymer Conjugates Of
			Therapeutic, Agricultural, And Food
5-881-WO-NO	N0200853IO	05/00/0007	Additive Compounds
	14020083310	05/22/2007	Preparation Of Polymer Conjugates Of
			Therapeutic, Agricultural, And Food
5-881-WO-NZ	NZ5728I6	05/22/2007	Additive Compounds
		00.22.2007	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food
F 004 1110 TV			Additive Compounds
5-881-WO-PH	PH I-2008-502500	05/22/2007	Preparation Of Polymer Conjugates Of
			Therapeutic, Agricultural, And Food
5-881 - WO-SG	SC2008 084608 6		Additive Compounds
	SG2008 084668-3	05/22/2007	Preparation Of Polymer Conjugates Of
			Therapeutic, Agricultural, And Food
-881-C	TW0966 8233	05/22/2007	Additive Compounds
		03/22/2007	Preparation Of Polymer Conjugates Of
·			Therapeutic, Agricultural, And Food Additive Compounds
-881-WO	PCT/US2007/069464		Preparation Of Polymer Conjugates Of
			Therapeutic, Agricultural, And Food
1	i		Additive Compounds

SCHEDULE B TO PATENT ASSIGNMENT PAGE 48 OF 53

$\underline{Schedule\;B}$

MBHB Case	Application No. /	Filing/Issued	Title				
No.	Patent No.	Date	1100				
		(mm/dd/yyyy)					
05-881-ZA-DIV	ZA20 0/08 98	05/22/2007	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food Additive Compounds				
05-881-WO-ZA	ZA2008/09564	05/22/2007	Preparation Of Polymer Conjugates Of Therapeutic, Agricultural, And Food				
05-553-WO-IL	iL188194	12/17/2007	Additive Compounds Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food				
05-553-WO-IN	IN5075/KOLNP/2007	12/28/2007	Additive Compounds Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food				
05-553-W0-JP	JP2008-520379	01/07/2008	Additive Compounds Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food				
05-553-WO-KR	KR2008-7002982	02/04/2008	Additive Compounds Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds				
05-553-WO-MX	MX MX/a/2008/000291 Patent No. 303295	07/072006	Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food				
05-553-WO-NZ	NZ564836	09/11/2012 07/07/2006	Additive Compounds Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food				
05.550.00	Patent No. 564836	02/07/2012	Additive Compounds				
05-553-SG-DIV	SG20 0 04810-6	07/07/2006	Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds				
05-553-WO-SG	SG2007-18828-7	07/07/2006	Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds				
05-553-WO-ZA	ZA2007/11116	07/07/2006	Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food				
05-553-WO-AU	Patent No. 2007/11116 AU2006269382	09/25/2008 07/07/2006	Additive Compounds Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food				
05-553-WO-BR	BR Pl0612407-0	07/07/2006	Additive Compounds Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds				
05-553-WO-CA	CA2614200	07/07/2006	Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds				
05-553-WO-CN	CN200680031902.5	07/07/2006	Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds				
05-553-WO-CO	C008012301	02/07/2008	Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food				
05-553-WO-EP	Patent No. 50046 EP06786449.6	08/24/2012 07/07/2006	Additive Compounds Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds				
05-553-CN-HK	HK09108998.6	09/29/2009	Preparation Of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds				
05-119-WO-AU	A U2006251620	05/22/2006	Imidazolone Phenylalanine Derivatives As VLA-4 Antagonists				
05-119-WO-BR	BR Pl0611285-4	05/22/2006	Imidazolone Phenylalanine Derivatives As VLA-4 Antagonists				

SCHEDULE B TO PATENT ASSIGNMENT PAGE 49 OF 53

MBHB Case No.	Application No. / Patent No.	Filing/Issued Date	Title
05-119-WO-CA	CA2608073	(mm/dd/yyyy)	
05-119-WO-CN		05/22/2006	Imidazolone Phenylalanine Derivatives As VLA-4 Antagonists
05-119-WO-EP	CN20068002461 0.	01/04/2008	Imidazolone Phenylalanine Derivatives As VLA-4 Antagonists
	EP06770821.4	05/22/2006	Imidazolone Phenylalanine Derivatives As VLA-4 Antagonists
05-119-CN-HK	HK08113753.2	05/22/2006	Imidazolone Phenylalanine Derivatives As VLA-4 Antagonists
05-119-WO-IN	IN4506/KOLNP/2007	11/22/2007	Imidazolone Phenylalanine Derivatives As
05-119-WO-JP	JP2008-512589	11/19/2007	VLA-4 Antagonists Imidazolone Phenylalanine Derivatives As VLA-4 Antagonists
05-119-WO-MX	Patent No. 5231215	03/29/2013	V D T + Antagornata
03-119-00-MX	MX/a/2007/014267	05/22/2006	Imidazolone Phenylalanine Derivatives As VLA-4 Antagonists
05-119-WO-NZ	Patent No. 293500 NZ563577	12/12/2011	
05-119-SG-DIV		05/22/2006	Imidazolone Phenylalanine Derivatives As VLA-4 Antagonists
05-119-WO-SG	SG2010 03303-3	05/22/2006	Imidazolone Phenylalanine Derivatives As VLA-4 Antagonists
05-119-WO-ZA	SG2007-17692-8	05/22/2006	Imidazolone Phenylalanine Derivatives As VLA-4 Antagonists
03-119-VVO-2A	ZA2007/09717	05/22/2006	Imidazolone Phenylalanine Derivatives As VLA-4 Antagonists
05-052-AR	Patent No. 2007/09717 AR P050102848	10/29/2008	
05-052-B7-AM		07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-B1	AM012433	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
00 002-51	AU2005265316	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052- B7-AZ	Patent No. 2005265316 AZ012433	05/17/2012	
05-052-B2		07/08/2005	Multimeric Via-4 Antagonist Compressing Polymer Moieties
05-052-B7-BY	BR PI0513143-0	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
	BY012433	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-WO-CA	CA2573245	07/08/2005	Multimeric VIa-4 Antagonist Compressing Polymer Moieties
05-052-C	CL1725-05	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-B4	CN200580029853.7	07/08/2005	Multimeric VIa-4 Antagonist Compressing Polymer Moieties
05 050 07	Patent No. 200580029853	03/28/2012	
05-052-B7	EA012433	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-B9	EC SP-07-7231	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-B8	EG16/2007	07/08/2005	Multimeric VIa-4 Antagonist Compressing Polymer Moieties
05-052-B6-DIV2	EP10179711.6	07/08/2005	Multimeric Vla-4 Antagonist Compressing
05-052-B6-DIV1	EP10179709.0	07/08/2005	Polymer Moieties Multimeric Vla-4 Antagonist Compressing
05-052-B6-DIV3	EP10180274.2	07/08/2005	Polymer Moieties Multimeric Vla-4 Antagonist Compressing
05-052-B6	EP05770402.5	07/08/2005	Polymer Moieties Multimeric Vla-4 Antagonist Compressing Polymer Moieties

Schedule B To Patent Assignment Page 50 OF 53

MBHB Case	Application No. /	Filing/Issued	Title
No.	Patent No.	Date	Title
		(mm/dd/yyyy)	
05-052-B5	HK07109071.6	08/21/2007	Multimeric Vla-4 Antagonist Compressing
05-052-B6-DIV2	HKIII09881.0	07/08/2005	Polymer Moieties Multimeric Via-4 Antagonist Compressing
05-052-B5-2	HK08102319.2	02/29/2008	Polymer Moieties Multimeric Vla-4 Antagonist Compressing
	Patent No. 1111674	12/28/2012	Polymer Moieties
05-052-B11	ID W-00200700049	07/08/2005	Multimeric VIa-4 Antagonist Compressing Polymer Moieties
05-052-B12	ILI80558	07/08/2005	Multimeric Vla-4 Antagonist Compressing
05-052-B10	IN131/KOLNP/2007	01/10/2007	Polymer Moieties Multimeric Vla-4 Antagonist Compressing
05-052-B10-DIV	IN4960/KOLNP/2011	12/09/2011	Polymer Moieties Multimeric Vla-4 Antagonist Compressing
05-052-B13	JP2007-520561	01/05/2007	Polymer Moieties Multimeric Vla-4 Antagonist Compressing
05-052- B7-KG	KGOI2433	07/08/2005	Polymer Moieties Multimeric Vla-4 Antagonist Compressing
05-052-B20	KR10-2007-70031 08	02/08/2007	Polymer Moieties Multimeric Vla-4 Antagonist Compressing
05-052- B7-KZ	KZOI2433	07/08/2005	Polymer Moieties Multimeric Vla-4 Antagonist Compressing
05-052-B15	MA29658	02/05/2007	Polymer Moieties Multimeric Vla-4 Antagonist Compressing
	Patent No. 28786	08/1/2007	Polymer Moieties
05-052- B7-MD	MDOI2433	07/08/2005	Multimeric VIa-4 Antagonist Compressing Polymer Moieties
05-052-B14	MX/a/2007/000228	01/08/2007	Multimeric VIa-4 Antagonist Compressing Polymer Moieties
	Patent No. 292893	12/01/2011	i orymer woreties
05-052-B17	N020070216	07/08/2005	Multimeric VIa-4 Antagonist Compressing Polymer Moieties
05-052-B16-DIV	NZ588839	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-B16	Patent No. 588839	01/04/2013	
00-002-616	NZ552521	07/08/2005	Multimeric Vla-4 Antagonist Compressing
05-052-D-DIV	PE260,12009	07/19/2005	Polymer Moieties
05-052-D	PE835/2005	07/19/2005	Multimeric VIa-4 Antagonist Compressing Polymer Moieties
	Patent No. 5410	09/10/2009	Multimeric VIa-4 Antagonist Compressing Polymer Moieties
05-052-B18	PH 1-2005-500057	01/05/2007	Multimeric VIa-4 Antagonist Compressing
05-052-B7-RU	RUOI2433	07/08/2005	Polymer Moieties Multimeric Vla-4 Antagonist Compressing
05-052-B21	SG2007001407	07/08/2005	Polymer Moieties Multimeric Vla-4 Antagonist Compressing Polymer Moieties
	Patent No. I28947	12/31/2008	LONGITION INICIONES
05-052-B7-TJ	TJOI2433	07/08/2005	Multimeric VIa-4 Antagonist Compressing Polymer Moieties
05-052- B7-TM	TMOI2433	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-G	TW094123303	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties
05-052-E	VE2005-001467	07/21/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties

Schedule B To Patent Assignment Page 51 OF 53 $\,$

MBHB Case No.	Application No. / Patent No.	Filing/Issued Date	Title
		(mm/dd/yyyy)	
05-052-B19	ZA2007/000238	07/08/2005	Multimeric VIa-4 Antagonist Compressing Polymer Mojeties
	Patent No. 2007/00238	07/30/2008	1 Olymon Molecies
05-052-B	PCT/US05/24369	07/08/2005	Multimeric Vla-4 Antagonist Compressing Polymer Moieties

SCHEDULE B TO PATENT ASSIGNMENT PAGE 52 OF 53

Country	Serial No.	Filing Date	Publication No.	Patent No.	Grant Date
Australia	2006231511	04-Apr-06		2006231511	31-May-12
Australia 01	2012202823	04-Apr-06		2000231311	31-Way-12
Canada	2603481	04-Apr-06			
China	200680019422.7	04-Apr-06	CN 101351710A		
Europe	06749243.9	04-Apr-06	1872136		
Europe 01	13158951.7	04-Apr-06	10,2150		
Hong Kong	08107142.4	04-Apr-06	1112059A		
India	4955/CHENP/2007	04-Apr-06	11120371	 	
Israel	186431	04-Apr-06		196421	20.7
Japan	2008-505451	04-Apr-06		186431	30-Jun-12
Japan 01	2011-213503	04-Apr-06			
New Zealand	562784	04-Apr-06		F. CO. TO .	
PCT	PCT/US2006/012493	04-Apr-06	WO2006/107962	562784	06-Nov-10
Singapore	200716554-1	04-Apr-06	W 02006/10/962	12/2/0	
				136340	30-Apr-10

SCHEDULE B TO PATENT ASSIGNMENT PAGE 53 OF 53

F&L Docket		Country	Application Number	Appl Date	1	Grant Date
342837-139	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS		03731419.2	5/27/200	Number 3 1507775	12/31/200
342837-160	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS		200401562	5/27/200	3 008256	4/27/2007
342837-136	7 HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Mexico	PA/a/2004/010 995	5/27/2003	3 268526	7/22/2009
342837-1392	COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Netherlands	03731419.2	5/27/2003	1507775	12/31/2008
342837-1369	COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Norway	20043900	5/27/2003	329933	1/24/2011
342837-1368	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	New Zealand	535504	5/27/2003	535504	3/9/2006
342837-1351	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	P.C.T.	PCT/US2003/01 6804	5/27/2003		
342837-1370	HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA 4 INTEGRINS	Philippines	1-2004-501523	5/27/2003	1-2004- 501523	6/30/2009

SCHEDULE B TO PATENT ASSIGNMENT PAGE 33 OF 53

F&L Docket No.	Title	Country	Application	Appl Date	Patent	Grant Date
342837-1606	HETEROCYCLIC	n	Number		Number	
	COMPOUNDS WHICH	Russian	200401562	5/27/2003	008256	4/27/200
	INHIBIT LEUKOCYTE	Federation				,,
	ADHESION				ı	
						ł
	MEDIATED BY ALPHA			1		
342837-1372	4 INTEGRINS					
342037-1372	THE CHOCKETC	Singapore	200405708-9	5/27/2003	106956	13/30/300
	COMPOUNDS WHICH			,=:,===	100550	12/29/2000
	INHIBIT LEUKOCYTE			ľ		
	ADHESION					
	MEDIATED BY ALPHA					
	4 INTEGRINS				1	
342837-1607	HETEROCYCLIC	Tajikistan	200401562	F/27/2002		
	COMPOUNDS WHICH	-	200401302	5/27/2003	008256	4/27/2007
	INHIBIT LEUKOCYTE					
	ADHESION					
	MEDIATED BY ALPHA					
	4 INTEGRINS					
342837-1608	HETEROCYCLIC	Turkmenistan	200401562	E/27/2002		
	COMPOUNDS WHICH		200401302	5/27/2003	008256	4/27/2007
	INHIBIT LEUKOCYTE			1		
	ADHESION				Ī	
	MEDIATED BY ALPHA					
	4 INTEGRINS				1	
42837-1352	HETEROCYCLIC	Taiwan	092114183	F/26/2002	1201	
	COMPOUNDS WHICH		032114183	5/26/2003	1281470	5/21/2007
	INHIBIT LEUKOCYTE					
	ADHESION					
j	MEDIATED BY ALPHA					
	4 INTEGRINS					
42837-1377	HETEROCYCLIC	Ukraine	20041008397	E/27/2002	75000	
	COMPOUNDS WHICH		200 11000337	5/27/2003	76339	7/17/2006
	INHIBIT LEUKOCYTE					
l	ADHESION					
1	MEDIATED BY ALPHA					
	4 INTEGRINS					
42837-1374	HETEROCYCLIC	Vietnam	1-2004-00949	E/37/2002	5005	
	COMPOUNDS WHICH		1-2004-00949	5/27/2003	6926	3/17/2008
	INHIBIT LEUKOCYTE					
	ADHESION					
	MEDIATED BY ALPHA					
	4 INTEGRINS					
	1,5	South Africa	2004/7590	5/27/2002	2004/755	12.6
[COMPOUNDS WHICH		2304/7330	1	2004/759	10/25/2006
	INHIBIT LEUKOCYTE				0	
	ADHESION					
	MEDIATED BY ALPHA					1
	4 INTEGRINS			1		

SCHEDULE B TO PATENT ASSIGNMENT PAGE 34 OF 53

F&L Docket No.	Title	Country	Application Number	Appl Date	Patent Number	Grant Date
342837-4012	PYRIMIDINE HYDANTOIN ANALOGUES WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	P.C.T.	PCT/US2005/01 4885	4/29/2005	Number	
342837-4061	Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Australia	2006297180	9/28/2006		
342837-4062	Carbamate Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Brazil	PI0616643-1	9/28/2006		
342837-4064	Carbamate Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	China P.R.	200680035707. X	9/28/2006		
342837-4065	Carbamate Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	European Patent Office	06804266.2	9/28/2006	1940827	3/16/2011
342837-4072	Carbamate Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Switzerland	06804266.2	9/28/2006	1940827	3/16/2011
342837-4073	Carbamate Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Germany	06804266.2	9/28/2006	1940827	3/16/2011
342837-4074	Carbamate Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	France	06804266.2	9/28/2006	1940827	3/16/2011
342837-4075	Carbamate Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	United Kingdom	06804266.2	9/28/2006	1940827	3/16/2011
342837-4076	Carbamate Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Ireland .	06804266.2	9/28/2006	1940827	3/16/2011

SCHEDULE B TO PATENT ASSIGNMENT PAGE 35 OF 53

F&L Docket No.		Country	Application	Appl Date	Patent	Grant Da
342837-407	Carbamate Compounds Which Inhibit Leukocyte Adhesion Mediated by VLA-4	Hong Kong	08112826.7	9/28/2006	Number	
342837-406	6 CARBAMATE	la dia				
	COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	India	800/KOLNP/20 08	9/28/2006		
342837-406	COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Japan	2008-533682	9/28/2006	5081828	9/7/20
342837-4077	COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION	Japan	2012-16870	9/28/2006		
342837-4068	COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION	Mexico	MX/a/2008/004 136	9/28/2006		
342837-4069	MEDIATED BY VLA-4 Carbamate					
	Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	New Zealand	567296	9/28/2006		
42837-4063	Carbamate Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Canada	2624524	9/28/2006		
42837-4060	Carbamate Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	P.C.T.	PCT/US2006/03 8113	9/28/2006		
42837-5011	PYRIMIDINYL AMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Australia	2006297220		20062972 20	11/22/2012
2837-5012	Pyrimidinyl Amide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Brazil	PI0616887-3	9/28/2006		<u></u>

SCHEDULE B TO PATENT ASSIGNMENT PAGE 36 OF 53

F&L Doc No.		Title	Country	Application Number	Appl D	ate	Patent	Grant D
342837-	5013	Pyrimidinyl Amide Compounds Which Inhibit Leukocyte Adhesion Mediate	1	2624450	9/28/2	2006	Numb	er
342837-5	01.4	By VLA-4		1	1			ĺ
342037-5	014	PYRIMIDINYL AMI	DE China P.R.	2000000				
		COMPOUNDS WHI INHIBIT LEUKOCYT ADHESION MEDIATED BY VLA-	CH E	2006800356 1	54. 9/28/2	006	ŽL 200680 5654.1	03
342837-5	015	Pyrimidinyl Amide Compounds Which	Colombia	08030304	9/28/20	006		
342837-50		Inhibit Leukocyte Adhesion Mediated By VLA-4	1					
0 12037-30		PYRIMIDINYL AMIDE COMPOUNDS WHIC INHIBIT LEUKOCYTE ADHESION	Eurasian Pat. H Convention	200800975	9/28/20	06 (015388	8/30/20:
342837-503	<u> </u> 1.7 [MEDIATED BY VLA-4 Pyrimidinyl Amide	European					
	II A	Compounds Which Thibit Leukocyte Idhesion Mediated Y VLA-4	Patent Office	06804253.0	9/28/200	06 1	940826	12/29/201
342837-503	0 P	YRIMIDINYL AMIDE	European		1			
	IN AI M	OMPOUNDS WHICH IHIBIT LEUKOCYTE DHESION EDIATED BY VLA-4	Patent Office					
342837-5031	Co Inf Ad By	rimidinyl Amide impounds Which nibit Leukocyte hesion Mediated VLA-4	Switzerland	06804253.0	9/28/2006	19	40826	12/29/2010
42837-5032	Coi Inh Adi	rimidinyl Amide mpounds Which ibit Leukocyte nesion Mediated VLA-4	Germany	06804253.0	9/28/2006	602 929		12/29/2010
42837-5033	Pyri Con Inhi	midinyl Amide pounds Which bit Leukocyte esion Mediated	Denmark	06804253.0	9/28/2006	194	0826	12/29/2010
2837-5034	By V Pyrii Com Inhib	LA-4 midinyl Amide pounds Which pit Leukocyte esion Mediated	France	06804253.0	9/28/2006	1940	826	12/29/2010

SCHEDULE B TO PATENT ASSIGNMENT PAGE 37 OF 53

F&L Docket No.	Title	Country	Application Number	Appl Date	Patent Number	Grant Date
342837-5035	Pyrimidinyl Amide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	United Kingdom	06804253.0	9/28/2006		12/29/2010
342837-5036	Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Ireland	06804253.0	9/28/2006	1940826	12/29/2010
342837-5037	Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Sweden	06804253.0	9/28/2006	1940826	12/29/2010
342837-5028	Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4	Hong Kong	08113271.5	9/28/2006		
342837-5018	Pyrimidinyl Amide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Indonesia	W00200800840	9/28/2006		
342837-5019	Pyrimidinyl Amide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Israel	190084	9/28/2006		
342837-5020	Pyrimidinyl Amide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	India	1046/KOLNP/2 008	9/28/2006		
342837-5021	PYRIMIDINYL AMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Japan	2008-533649	9/28/2006	5101512	10/5/2012
342837-5022	Pyrimidinyl Amide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	South Korea	10-2008- 7010301	9/28/2006		
342837-5023	PYRIMIDINYL AMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Mexico	MX/a/2008/004 030	9/28/2006	288343	1/25/2011

Schedule B To Patent Assignment Page 38 OF 53 $\,$

F&L Docket	Title	Country	Application	Appl Date	Patent	Grant Date
No.]		Number		Number	
342837-5024	PYRIMIDINYL AMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Norway	20082002	9/28/2006		
342837-5025	Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4	New Zealand	567270	9/28/2006	567270	10/10/2011
342837-5010	Pyrimidinyl Amide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	P.C.T.	PCT/US2006/03 8009	9/28/2006		
342837-5026	Pyrimidinyl Amide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Philippines	1-2008-500753	9/28/2006		
342837-5027	Pyrimidinyl Amide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	South Africa	2008/03280	9/28/2006	2008/032 80	11/29/2009
342837-5029	Pyrimidinyl Amide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	South Africa	2009/06610	9/28/2006	2009/066 10	5/25/2011
342837-5061	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Argentina	070100812	2/27/2007		
342837-5063	PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Australia	2007220068	2/26/2007		
342837-5085	PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Australia	2012261691	2/26/2007		

Schedule B To Patent Assignment Page 39 OF 53

F&L Docket No.	Title	Country	Application	Appl Date	Patent	Grant Date
342837-5064	Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Brazil	Number 0708331-9	2/26/2007	Number	
342837-5065	Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Canada	2643838	2/26/2007		
342837-5066	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	China P.R.	200780006583. 7	2/26/2007	ZL 20078000 6583.7	7/18/2012
342837-5075	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Médiated By VLA-4	Colombia	08.096.101	2/26/2007		
342837-5076	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Eurasian Pat. Convention	200801906	2/26/2007	017110	9/28/2012
342837-5086	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Armenia				
342837-5087	PYRIMIDINYL SULFONAMIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4	Azerbaijan	200801906	2/26/2007	017110	9/28/2012
	Pyrimidinyl Sulfonamide Compounds Which Inhibit Leukocyte Adhesion Mediated By VLA-4	Belarus	200801906	2/26/2007	017110	9/28/2012

SCHEDULE B TO PATENT ASSIGNMENT PAGE 40 OF 53

PATENT REEL: 059098 FRAME: 0626

RECORDED: 08/06/2028